

CURRICULUM VITAE

Michael James Haller, MD, MS-CI

Professor, 2016-
Department of Pediatrics
University of Florida

Chief, Pediatric Endocrinology, 2016-
Silverstein Family Eminent Scholar Chair, 2016-
Program Director, Pediatric Endocrinology Fellowship, 2011-2018
University of Florida

Residence:
8552 SW 12 Lane
Gainesville, FL 32607 USA

University of Florida
PO Box 100296
Gainesville, FL 32610 USA
Tel : 352.273.9264
Fax: 352.273.9364
EMAIL: hallemj@peds.ufl.edu

BIRTH: March 28, 1975 Gainesville, FL, USA

FAMILY: Wife: Allison Sherman Haller, MD – Married, March 9, 2003
Daughter: Zoe Elizabeth Haller – Born, May 5, 2009
Son: Jack Elias Haller – Born October 5, 2012

EDUCATION/TRAINING:

1988-1992	Gainesville High School, Gainesville, FL Valedictorian
1992-1996	Duke University, Durham, N.C. Biology major, Chemistry minor Cum Laude with Distinction B.S. 1996
1996-2000	University of Florida, Gainesville FL College of Medicine M.D. 2000
2000-2003	Pediatric Resident University of Florida, College of Medicine

2003-2006	Pediatric Endocrinology Fellow University of Florida, College of Medicine
2004-2006	Advanced Program in Postgraduate Clinical Investigation (APPCI) University of Florida, College of Medicine M.S. in Clinical Investigation 2006
2006-2011	Assistant Professor Pediatric Endocrinology University of Florida
2011-2016	Associate Professor (Tenured) Pediatric Endocrinology
2016-	Professor Pediatric Endocrinology

QUALIFICATIONS:

USMLE Step 1: 215 06/09/1998
 USMLE Step 2: 218 12/13/1999
 USMLE Step 3: 221 10/16/2001
 Diplomat, American Board of Pediatrics: 2004
 Fellow, American Academy of Pediatrics: 2006
 AACE Certified in Thyroid US and FNA Biopsy: 2006
 Certified Clinical Densitometrist (CCD): 2006
 Diplomat, American Board of Pediatrics, Endocrinology: 2007

LICENSURE:

Florida Medical Licensure: ME 91175

SPECIAL ACHIEVEMENTS:

Eagle Scout – 1988
 Valedictorian, Gainesville High School – 1992
 PIMS Award – Medical student most dedicated to education of class -1997
 Albert Stickler Memorial Scholarship -1998, 1999
 University of Florida College of Medicine Human Development Award – 2000
 Douglass J. Barrett Fellowship Award – 2004 / 2005
 Henry Kokomor Award – Outstanding Fellow – 2005
 NIH Pediatric Research Loan Repayment, 2005-2007
 ADA Young Investigator Travel Award -2007
 JDRF Early Career Clinical Research Award – 2007

NIH Pediatric Research Loan Repayment, Competitive Renewal, 2007-2009
JDRF Mary Tyler Moore Excellence in Clinical Research Award – 2008
Society for Pediatric Research – 2008
ADA Cure Award -2009
NIH Pediatric Research Loan Repayment, Competitive Renewal, 2009-2011
University of Florida, Excellence Award for Research, Assistant Professors, 2010
ISPAD Young Investigator Award – 2010
UF College of Medicine Leadership Development Program – 2015
University of Florida Term Professorship - 2016-17
University of Florida Research Foundation (UFRF) Professorship – 2017-2020

PROFESSIONAL ORGANIZATIONS:

American Board of Pediatrics, 2000
American Diabetes Association, 2003
International Society for Pediatric and Adolescent Diabetes, 2003
American Association of Clinical Endocrinologists, 2005
Lawson Wilkins Pediatric Endocrine Society – Associate Member, 2003-07
Lawson Wilkins Pediatric Endocrine Society, Member 2007
Florida Medical Association, 2007
Florida Diabetes Camp: Board Member, 2006-
Vice President, 2008-
TrialNet Researcher, 2005-
TEDDY Researcher, 2007-

COMMITTEE ASSIGNMENTS:

TrialNet: Oral Insulin Subcommittee member, 2007-
Anti-CD20 Site PI, Subcommittee member, 2007-
GAD Prevention Subcommittee member, 2008-
CTLA-4 Subcommittee member, 2008-
Eligibility Committee: 2010-
Clinical Monitoring Committee: 2011-
Clinical Feasibility Committee: 2011-
Chair, TN19, ATG/GCSF in New-Onsets
Chair, TN28, ATG in Prevention
Site PI, 2019-
TEDDY: Co-chair, Clinical Implementation Committee, 2007-
T1D Exchange: Biobank Scientific Review Committee: 2011-
Vice-Chair, Biobank: 2012-
NIH: NIH LRP Ambassador: 2011-
ADA: Health Care Professionals Legal Advocacy Network, 2008-
Research Grant Review Committee: 2009-2012
Scientific Sessions Youth Subcommittee: 2012-
Chair, Youth Scientific Sessions: 2019-
JDRF: Medical Science Review Committee (MSRC)

UF: Strategic Planning Education Committee, 2008-
Graduate Faculty, PhD Supervisory Committees: 2009-
Search Committee, Grants Administrator: 2010
Associate Program Director, Fellowship: 2008-2011
Program Director, Fellowship: 2011-2018
Division Chief, 2016-
Chair, Department of Pediatrics Finance Committee, 2019-
Pediatrics Education Taskforce: 2012-
CTSI/TRACTS: Advisory Committee: 2012-2018
PES Research Affairs Council 2016-2019

TRAINEES:

2005-2008 Angelina Valladares MD, Assistant Professor, University of Florida
2006-2009 Henry Rohrs MD, Associate Professor, University of Florida
2007-2010 Lisa Gallo MD, Assistant Professor, University of South Carolina
2008-2011 Laurie Minarich-Tsilianidis MD, Cleveland, OH
2010-2013 Joyce Gan MD, Assistant Professor, Johns Hopkins All Children's Hospital
2011-2014 Rena Abraham-Harrington, Pediatrician in Ocala
2012-2015 Biomata Nanbam, Assistant Professor, Johns Hopkins, Tampa, FL
2013-2016 Colette Meehan, Palm Beach Gardens, FL
2014-2017 Giovanna Beauchamp, Assistant Professor, UAB
2015-2018 Kristin Dayton, Assistant Professor, University of Florida
2015-2018 Laura Jacobsen, Assistant Professor, University of Florida
2017-2020 Paul Hiers

PhD:

Yaima Lazuardo Lightfoot, PhD: 2008-2012
Young Mee Yoon, PhD: 2010-2014
Brittney Newby: MD, PhD: 2014-2019
Madison Smith, PhD: 2015-2019
Andrea Lin, PhD Candidate: 2016-
Ke Ding, PhD Candidate: 2018-

EDITORIAL:

Ad hoc Reviewer:
Diabetes Care: 2003-
Journal of Clinical Endocrinology and Metabolism: 2004-
Pediatrics: 2004-
Journal of Pediatrics: 2004-
Pediatric Diabetes: 2004-
Journal of Pediatric Endocrinology and Metabolism: 2004-
Endocrine Fellows Foundation: 2004-
Nature, Clinical Practice Endocrinology & Metabolism: 2006-
Expert Opinion on Biological Therapy: 2007-

Clinical and Experimental Immunology: 2008-
Journal of Diabetes and Its Complications: 2008-
Diabetes Research and Clinical Practice: 2008-
American Journal of Clinical Nutrition: 2009-

Editorial Board:

Endocrinology Today: 2007-2008

Review of Endocrinology: 2008-2010

AAP Pediatrics Review and Education Program (PREP): 2010-2013

Medical Advisory Board:

Diabetes Action Research and Education Foundation: 2007-

Novo Nordisk Pediatric Basal/Bolus Board: 2008-

International Telecommunications Education and Research Association 2009-

SAB Biotherapeutics – Scientific Advisory Board, 2016-

Help A Diabetic Child, Medical Director: 2017-

Grant Reviewer / Study Sections:

Endocrine Fellows Foundation: 2006-

Health Research Council of New Zealand: 2009-

JDRF: Autoimmunity Study Section, 2009-2014

Prevention T1D Study Section, 2013

PES Fellowship Awards: 2013-

NIH ZDK1 GRB-J(01) Type 1 Diabetes Impact Award Study Section: 2011-

NIH ZAI1 JTS-I Special Emphasis Panel/Scientific Review Group: 2011-

NIH/NIAID: ZAI1 PA-I (J2) Statistical and Clinical Coordinating Center: 2014

FY19 RFA Review - Innovative Strategies to Demonstrate Immunological Proof-of-Mechanism and to Explore Early Outcome Measures in Immunotherapy Trials

GRANT SUPPORT (ACTIVE):

National Institutes of Health, U01 DK085461-06 (7/28/14-1/31/19 – Renewal Submitted)

Title: TrialNet: University of Florida Clinical Center and Network

Role: Co-PI (PI on renewal)

Total Award: \$687,463/year

NIH, TEDDY Study (6/1/13-)

Title: The Environmental Determinants of Diabetes in Youth

Role: Co-PI, Support: 5% FTE

National Institutes of Health, 1DP3DK101120-01 (9/20/13-8/31/16)

Title: Pancreatic Volume in Preclinical Type 1 Diabetes

Role: Co-PI

Total Award: \$1,398,453

The Leona M. & Harry B. Helmsley Charitable Trust
Board of Trustees of the Leland Stanford Junior University
ECHO T1D Phase 2
Role: PI (UF Site, Shared Grant with Stanford)
Total amount: \$7,690,665

National Institute of Health NIAID (6/20/18-5/31/2023)
Title: Immune Function P0-1
Role: Co-PI
Total Amount: \$8435.00

McJunkin Family Foundation (12/1/15-)
Title: Technology for Education in T1D
Role: PI
Total Award: \$200,000

McJunkin Family Foundation
Title: T Cell Therapies in T1D (12/15/15-)
Role: PI
Total Amount: \$500,000

Cord Blood Registry (6/1/16-06/30/20)
Title: Clinical Trial Planning Grant for Treg Therapy in Type 1 Diabetes
Role: PI
Total Amount: \$246,356

GRANT SUPPORT (COMPLETED):

Diabetes Action and Research Education Foundation, 2004-2005
Title: Endothelial Dysfunction in Children with Type 1 and Type 2 Diabetes
Role: Principal Investigator
Total Award: \$60,000

Diabetes Action and Research Education Foundation 2005-2006
Title: Endothelial Dysfunction in Children with Type 1 and Type 2 Diabetes
Role: Principal Investigator
Total Award: \$25,000 supplemental award

K30, APPCI Fellowship 2004-2006
Title: Advanced Postgraduate Program in Clinical Investigation
Role: Student
Total Award: Tuition and fees to complete master's in clinical investigation

Children's Miracle Network, Grant #2004-032, 2004.
Title: Differentiation of mouse embryonic stem cells into insulin producing cells-
formulation of a novel protocol using an anti-tumor drug, cyclopamine

Role: Co-Principal Investigator
Total Award: \$8,593.25

Pfizer Independent Research Grant #2004-0926, 2005-2007
Title: Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)
Role: Principal Investigator
Total Award: \$87,456

GCRC Grant M-01 RR 000082, 2005-2006
Title: Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT)
Role: Principal Investigator
Total Award: \$26,444.88

Diabetes Action Research and Education Foundation Grant #210, 2006-2007
Title: Longitudinal Follow-up of Arterial Stiffness and Endothelial Dysfunction in Children with Type 1 Diabetes
Role: Principal Investigator
Total Award: \$40,000

National Institutes of Health, 1R13DK080530-01 (2007)
Title: 9th Immunology of Diabetes Society Research Symposium
Role: Co-Principal Investigator
Total Award: \$15,000

JDRF Innovative Grant 4-2007-1065 (2005-2009)
Title: Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children with Type 1 Diabetes – A Pilot Study
Role: Co-Principal Investigator (12% FTE)
Total Award: \$319,220

Lawson Wilkins Clinical Scholar Award (2006-2008)
Title: Islet Regeneration in Animal Models of Type 1 Diabetes with Bone Marrow and Human Umbilical Cord Stem Cells
Role: Principal Investigator (0% FTE)
Total Award: \$100,000

National Institutes of Health, 1R21DK077580-01 (2006-2008)
Title: Cord Blood Immunoregulation of Type 1 Diabetes
Role: Co-Investigator (7.5% FTE)
Total Award: \$394,164

National Institutes of Health, 3R21DK078863 (2008-2010)
Title: Short Course GCSF as Immunomodulatory Therapy for type 1 Diabetes? A Pilot Study
Role: Primary Investigator (5% FTE)
Total Award: \$396,588

National Institutes of Health, 3R21DK078863-02S1 (2010)
ARRA Supplement
Title: Short Course GCSF as Immunomodulatory Therapy for type 1 Diabetes? A Pilot Study
Role: Primary Investigator (5% FTE)
Total Award: \$85,500

JDRF Early Career Clinical Investigator Supplemental Award (2008-2009)
Title: Novel Approaches to the Reversal of Type 1 Diabetes
Role: Primary Investigator (0 FTE)
Total Award: \$188,200

UF CTSI Major Initiative Award (2010-2012)
Title: Reversing Type 1 Diabetes After it is Established (Data Coordinating Center)
Role: Primary Investigator
Total Award: \$100,000

Viacord/Perkin-Elmer (7/1/13-12/31/14)
Title: Cord Blood Treg Expansion
Role: PI
Total Award: \$247,586

Diabetes Action Research and Education Foundation (1/1/14-12/31/14)
Title: Non Invasive Assessment of Pancreatic volume as a tool to augment risk stratification in patients at risk for type 1 diabetes
Role: Primary Investigator
Total Award: \$20,000

Helmsely Foundation (9/1/13-2/28/15)
Title: Reversing Type 1 Diabetes After it is established
Role: Primary Investigator, UF Site (Project #4)
Total Award: \$3,289,657

Helmsley Foundation (9/1/13-2/28/15)
Title: Reversing Type 1 Diabetes After it is Established, Long Term Follow up
Role: Primary Investigator
Total Award: \$237,540

Diabetes Action Research and Education Foundation (1/1/15-12/31/16)
Title: Acute Effect of a Mixed Meal With and Without Extra Insulin on Arterial Stiffness, a Prospective Randomized Study
Role: Primary Investigator
Total Award: \$6,592

T1D Exchange Biobank funded by The Helmsley Trust (2/2/12-2/29/16)
Title: T1D Exchange Biobank
Role: Vice-Chair for Biobank
Support: 25% FTE

CTSI Network Science Pilot Award
Title: Immunotherapy Plus Tolerogenic Microparticle Vaccine Combination Therapy for Type 1 Diabetes
Role Co-PI
Total Award: \$25,000

Helmsely Foundation (7/14-5/17)
Title: ATG/GCSF in New Onset T1D
Role: PI
Total Award: \$2,140,000

Sanofi/Genzyme – NIDDK
Title: ATG/GCSF in New Onset T1D
Role: PI
Total Award: \$4,026,000

Janssen Research and Development (12/15/16-10/31/18)
SIMPONI to Arrest B-Cell loss in Type 1 Diabetes- TIGER
Role: PI
Total Amount: \$38,729.68

PUBLICATIONS:

Peer Reviewed Manuscripts:

1. **Haller MJ**, Stalvey MS, Silverstein J. Predictors of control of diabetes: Monitoring may be the key. *J Pediatr.* 2004 May; 144(5):600-1. PMID 15127007
2. **Haller MJ**, Samyn M, Nichols WW, Brusko T, Wasserfall C, Schwartz RF, Atkinson M, Shuster JJ, Pierce GL, Silverstein JH . Radial Artery Tonometry Demonstrates Arterial Stiffness in Children with Type 1 Diabetes. *Diabetes Care.*2004 Dec; 27(12):2911-7. PMID 15562206
3. Williams CA, Wallace MR, Drury KC, Kipersztok S, Edwards RK, Williams RS, **Haller MJ** , Schatz DA, Silverstein JH, Gray BA, Zori RT. Blood lymphocyte chimerism associated with in vitro fertilization and monozygotic dizygous twinning. *Hum Reprod* 2004 Dec;19(12):2816-21.Epub 2004 Sep 16. PMID 15375077
4. **Haller M**, Schatz D. The Role of Leuprolide Acetate Therapy in Triggering Auto-immune Thyroiditis. *J Pediatr.* 2005 Feb;146(2):294; author reply 294-5. PMID 15689930

5. **Haller MJ**, Atkinson MA, Schatz D. Type 1 diabetes mellitus: etiology, presentation, and management. *Pediatr Clin North Am.* 2005 Dec;52(6):1553-78. Review. PMID: 16301083
6. **Haller MJ**, Schatz DA. CD3-antibody therapy in new-onset type 1 diabetes mellitus. *N. Engl J. Med.* 2005 Nov 10;353(19):2086-7; author reply 2086-7. PMID 16282188
7. **Haller MJ**, Pierce GL, Braith RW, Silverstein JH. Serum Superoxide Dismutase Activity and Nitric Oxide Do Not Correlate with Arterial Stiffness in Children with Type 1 Diabetes. *J Pediatric Metabolism and Endocrinology.* 2006 Mar;19(3):267-9 PMID 16607928
8. **Haller MJ**, Valladares A, Rosenbloom AL. Arterial Thrombosis Resulting In Amputation In A Child With Poorly Controlled Type 1 Diabetes And Heterozygous Factor V Leiden Mutation. *Pediatr Diabetes.* 2006 Aug;7(4):229-31. PMID 16911011
9. **Haller MJ**, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A, Mahmud FH. Peripheral Artery Tonometry Demonstrates Altered Endothelial Function In Children With Type 1 Diabetes. *Pediatric Diabetes.* 2007 Aug;8(4):193-8. PMID 17659060
10. **Haller MJ**, Shuster J, Schatz D, and Melker RJ. Adverse Impact of Temperature and Humidity on Blood Glucose Monitoring Reliability: A Pilot Study. *Diabetes Technol Ther.* 2007 Feb;9(1):1-99(1):1-9, 2007. PMID 17316092
11. Zineh I, Beitelshes AL, **Haller MJ**. NOS3 Polymorphisms are Associated with Arterial Stiffness in Children with Type 1 Diabetes. *Diabetes Care.* 2007 Mar;30(3):689-93. PMID 17327342
12. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, **Haller M**, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes. *Diabetes* 2007 Mar;56(3):604-12. PMID 17327427
13. Brown JL, Burton DW, Deftos, LJ, Smith AA, Pincus D, **Haller MJ**. Congenital Craniopharyngioma and Parathyroid Hormone – Related Protein (PTHrP) Induced Hypercalcemia. *Endocr Pract.* 2007 Jan-Feb;13(1):67-71. PMID 17360305
14. **Haller MJ**, Silverstein JH, Shuster JJ. Correlation between Radial Artery Tonometry and Fingertip Tonometry Derived Augmentation Index in Children with Type 1 Diabetes. *Diab Vasc Dis Res.* 2007 Mar;4(1):66. PMID 17469047
15. **Haller MJ**, DA Schatz. Endocrine Complications of Pediatric Cancer Therapy: Evaluation and Management. *Pediatr Endocrinol Rev.* 2007 Mar;4(3):196-204. PMID 17551480

16. **Haller, MJ**, Gottlieb, PA, and DA Schatz. Type 1 Diabetes Intervention Trials: Where are We and Where are We Going? *Curr Opin Endocrinol Diabetes Obes.* 2007 Aug;14(4):283-7. PMID 17940453
17. Park JY, Chong AY, Cochran EK, Kleiner DE, **Haller MJ**, Schatz, DA, Gorden P. Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy. *J Clin Endocrinol Metab.* 2008 Jan;93(1):26-31. Epub 2007 Oct 16. PMID 17940115 PMCID: PMC2729152
18. Brusko TM, Hulme MA, Myhr CB, **Haller MJ**, Atkinson MA. Assessing the In Vitro Suppressive Capacity of Regulatory T Cells. *Immunol Invest.* 2007;36(5-6):607-28. PMID 18161521
19. Horsman T, Schatz DA, **MJ Haller**. Cardiomyopathy and Hypocalcemia: A Unified Explanation? *Contemporary Pediatrics.* 20-25, Jan 2008.
20. **Haller MJ**, Schatz DA. Cytokines and Type 1 Diabetes Complications: Casual or Causal Association? *Pediatr Diabetes.* 2008 Feb;9(1):1-2. doi: 10.1111/j.1399-5448.2007.00364.x PMID 18211629
21. **Haller MJ**, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous Umbilical Cord Blood Infusion for Type 1 Diabetes. *Exp Hematol.* 2008 Jun;36(6):710-5. doi: 10.1016/j.exphem.2008.01.009. Epub 2008 Mar 20. PMID 18358588 PMCID: PMC2444031
22. **Haller MJ** and Schatz DA. What's in a name. Thyroid autoimmunity in obese patients with T1D. *Pediatr Diabetes.* 2008 Jul 28;9(4 Pt 1):263-5. doi: 10.1111/j.1399-5448.2008.00368. PMID 18768034
23. Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, McCampbell-Thompson M, Schatz DA, Atkinson MA, **Haller MJ**. Exendin-4 Therapy in New Onset Nod Mice Increases Regulatory T Cell Frequency. *Ann N Y Acad Sci.* 2008 Dec;1150:152-6. doi: 10.1196/annals.1447.049. PMID 19120286
24. Rosenbloom AL, Guevara-Aguirre J, **Haller MJ**, Malasanos TH, Miller JL, Rohrs HJ, Schatz DA, Silverstein JH, Weinstein DA. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature *JCEM*, Jan 14 2009. <http://jcem.endojournals.org/cgi/eletters/93/11/4210> Letter.
25. Zineh I, Beitelshees A, Silverstein JH, **Haller MJ**. Serum MCP-1 Concentrations Associate with Diabetes Status but not Arterial Stiffness in Children with Type 1 Diabetes. *Diabetes Care.* 2009 Mar;32(3):465-7. doi: 10.2337/dc08-1849. Epub 2008 Dec 17. PMID 19092169 PMCID: PMC2965824
26. **Haller MJ**, Stein J, Shuster JJ, Theriaque D, Samyn MM, Pepine CJ, Silverstein JH. Pediatric Atorvastatin in Diabetes Intervention Trial (PADIT-1): A Pilot Study to

- Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes. *J Pediatr Endocrinol Metab.* 2009 Jan;22(1):65-8 PMID 19344076 PMCID: PMC3621084
27. Bernier AV, Correia CE, **Haller MJ**, Theriaque D, Shuster J, Weinstein DA. Vascular dysfunction in glycogen storage disease type I. *J Pediatr.* 2009 Apr;154(4):588-91. doi: 10.1016/j.jpeds.2008.10.048. Epub 2008 Dec 21. PMID 19101686 PMCID: PMC3607442
 28. **Haller MJ**, Silverstein JH. In Pursuit of Lower A1c. *J Pediatr.* 2009 Aug;155(2):161-2. doi: 10.1016/j.jpeds.2009.03.006 PMID 19619746
 29. **Haller MJ**, Atkinson MA, Schatz DA . The Road Not Taken: A Path to Curing Type 1 Diabetes. *Eur J Immunol.* 2009 Aug;39(8):2054-8. doi: 10.1002/eji.200939517. PMID 19672902 PMCID: PMC4085751
 30. Gittleman SE, **Haller MJ**, Schatz DA. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in newly diagnosed Type 1 Diabetes. *JAMA.* 2009 Aug 12;302(6):624; author reply 624-5. doi: 10.1001/jama.2009.1098 PMID 19671901
 31. Parker MJ, Xue S, Alexander J, Wasserfall CH, Campbell-Thompson ML, Battaglia M Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, **Haller MJ**, Atkinson MA . Immune depletion with cellular imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice. *Diabetes.* 2009 Oct;58(10):2277-84. doi: 10.2337/db09-0557. Epub 2009 Jul 23 PMID 19628781 PMCID: PMC2750219
 32. Bierschenk L, Alexander J, Wasserfall C, **Haller M**, Schatz, D, Atkinson M. Vitamin D Levels in Subjects with and without Type 1 Diabetes Residing in a Solar Rich Environment. *Diabetes Care* 2009 Nov;32(11):1977-9. doi: 10.2337/dc09-1089. Epub 2009 Aug 12 PMID: 19675194
 33. **Haller MJ**, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard, JR, Kelly SS, Shuster JJ, Atkinson MA, Schatz DA. Autologous Umbilical Cord Blood Transfusion in Very Young Children with Type 1 Diabetes. *Diabetes Care* 2009 Nov;32(11):2041-6. doi: 10.2337/dc09-0967. PMID 19875605 PMCID: PMC2768209
 34. Schatz DA, **Haller MJ**, Atkinson MA. Type I diabetes. Preface. *Endocrinol Metab Clin North Am.* 2010 Sep;39(3):xvii-xviii. doi: 10.1016/j.ecl.2010.05.012. Epub 2010 Jul 1. PubMed PMID: 20723814.
 35. Xue, S, Wasserfall S, Parker P, McGrail S, McGrail K, Campbell-Thompson M, Schatz DA, Atkinson MA, **Haller MJ**. Exendin-4 Treatment of Non-obese Diabetic Mice Increases Beta-cell Proliferation and Fractional Insulin Reactive Area. *J Diabetes Complications.* 2010 May-Jun;24(3):163-7. doi: 10.1016/j.jdiacomp.2008.12.004. Epub 2009 Feb 13. PMID 19217320

36. Gallo LM, Shuster JJ, Silverstein JD, **Haller MJ**. Arterial Stiffness, Lipoprotein Particle Size and Lipoprotein Particle Concentration in Children with Type 1 Diabetes. *J Pediatr Endocrinol Metab*. 2010 Jul;23(7):661-7 PMID: 20857838 PMCID: PMC3607441
37. Ma H, Lu Y, Li H, Campbell-Thompson M, Parker M, Wasserfall C, **Haller M**, Brantly M, Schatz D, Atkinson M, Song S. Prevention and reversal of type 1 diabetes in NOD mice by alpha 1 antitrypsin therapy. *Diabetologia*. 2010 Oct;53(10):2198-204. doi: 10.1007/s00125-010-1829-2. Epub 2010 Jul 1. PMID: 20593162
38. Silverstein J, **Haller M**. Coronary artery disease in youth: present markers, future hope? *J Pediatr*. 2010 Oct;157(4):523-4. doi: 10.1016/j.jpeds.2010.07.010. Epub 2010 Aug 21 PMID: 20728091
39. Vehik K, **Haller MJ**, Beam CA, Wherrett, DK, Sosenko JM, Krisher JP; DPT-1 Study Group. Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for repeat screening throughout childhood. *Diabetes Care*. 2011 Feb;34(2):358-62. doi: 10.2337/dc10-1494. PMID:21270193 PMCID:PMC3024349
40. Driscoll KA, Johnson SB, Schatz DA, **Haller MJ**. Use of a Precious Resource: parental decision making about using autologous umbilical cord blood in studies involving young children with Type 1 Diabetes. *Clinical Trials*. Jul;32(4):524-9, 2011. PMID:21530680 PMCID: PMC3129744
41. Ize-Ludlow D, Lightfoot YL, Parker M, Xue S, Wasserfall C, **Haller MJ**, Schatz D, Becker DJ, Atkinson MA, Mathews CE. Progressive Erosion of Beta Cell Function Precedes the Onset of Hyperglycemia in the NOD Mouse Model of Type 1 Diabetes. *Diabetes* 2011 Aug;60(8):2086-91. doi: 10.2337/db11-0373. Epub 2011 Jun 9. PMID: 21659497 PMCID: PMC3142079
42. Vehik K, Beam CA, Mahon JL, Schatz DA, **Haller MJ**, Sosenko JM Skyler JS, Krischer JP; TrialNet Natural History Study Group. Development of Autoantibodies in the TrialNet Natural History Study (NHS). *Diabetes Care*. 2011 Sep;34(9):1897-901. doi: 10.2337/dc11-0560. Epub 2011 Jul 12. PMID: 21750277 PMCID: PMC3161292
43. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, **Haller M**, Schatz D, Myhr C, She JX, Wasserfall C, Atkinson M. Reduced Serum Vitamin D Binding Protein Levels are Associated with Type 1 Diabetes. *Diabetes*. 2011 Oct;60(10):2566-70. doi: 10.2337/db11-0576. Epub 2011 Aug 15 PMID: 21844098 PMCID: PMC3178281
44. Serreze DV, Chapman HD, Niens M, Dunn R, Kehry MR, Driver JP, **Haller M**, Wasserfall C, Atkinson MA. Loss of intra-islet CD20 expression may complicate efficacy of B-lymphocyte directed type 1 diabetes therapies. *Diabetes*. 2011 Nov;60(11):2914-21. doi: 10.2337/db11-0705. Epub 2011 Sep 16. PMID:21926271 PMCID: PMC3198088

45. Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C, Knip M, Veijola R, Lindblad B, Samuelsson U, Holl R, **MJ Haller**;TEDDY study group, SEARCH study group, Swediabkids study group, DPV study group, and Finnish Diabetes Registry study group. Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up. *Diabetes Care*. 2011 Nov;34(11):2347-52. doi: 10.2337/dc11-1026. Epub 2011 Oct 4. PMID:21972409 PMCID:PMC3205351
46. Grajower MM, Zangen D, **Haller, MJ** member of writing group. Expert Opinion and Clinical Experience Regarding Patients with Type 1 Diabetes Mellitus Fasting on Yom Kippur. *Pediatr Diabetes*. 2011 Aug;12(5):473-7. doi: 10.1111/j.1399-544848.2011.00801.x. PMID:21794045
47. **Haller MJ**, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Sumrall TM, Wingard JR, Theriaque DW, Shuster JJ, Atkinson MA, Schatz DA. Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide. *Diabetes Care*. 2011 Dec;34(12):2567-9. doi: 10.2337/dc11-1406. Epub 2011 Oct 19. PubMed PMID: 22011412; PubMed Central PMCID: PMC3220832.
48. Vehik K, **Haller MJ**, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J;the DPT-1 Study Group. Islet Autoantibody Seroconversion in the DPT-Study: Justification for Repeat Screening Throughout Childhood. *Diabetes Care* 2011Feb;34(2):358-62. doi: 10.2337/dc10-1494. PMID 21270193 PMCID: PMC3024349
49. Rosenau EH, Sugrue MW, **Haller M**, Fisk D, Kelly SS, Chang M, Hou W, Eldjerou L, Slayton W, Cogle CR, Wingard JR. Characteristics of Thawed Autologous Umbilical Cord Blood. *Transfusion*. 2012 Oct;52(10):2234-42. doi: 10.1111/j.1537-2995.2011.03556.x. Epub 2012 Feb 10. PMID:22321210
50. Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun JP, Cengiz E, **Haller MJ**, Hassan K, Klingensmith GJ, Tamborlane WV. Accuracy and precision of the axis-shield afinion hemoglobin a1c measurement device. *J Diabetes Sci Technol*. 2012 Mar 1;6(2):380-6. PMID:22538150
51. Greenbaum CJ, Schatz DA, **Haller MJ**, Sanda S. Through the Fog: Recent Clinical Trials To Preserve Beta Cell Function in Type 1 Diabetes. *Diabetes*. 2012 Jun;61(6):1323-30. doi: 10.2337/db11-1452. PMID: 22618767 PMCID: PMC3357268
52. Topiol ES, Minarich LA, Williams CA, Zori RT, Kays DW, and **MJ Haller**. Neonatal diabetes mellitus and congenital diaphragmatic hernia: coincidence or concurrent etiology? *Int J Pediatr Endocrinol*. 2012 Jul 10;2012(1):21. doi: 10.1186/1687-9856-2012-21. PMID:22781086 PMCID: PMC3408326
53. Klingensmith GJ, Tamborlane WV, Wood J, **Haller MJ**, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW; Pediatric Diabetes Consortium. Diabetic Ketoacidosis at Diabetes Onset: Still an All Too Common Threat

- in Youth. *J Pediatr*. 2013 Feb;162(2):330-4.e1.doi;10.1016/j.peds.2012.06.058. Epub 2012 Aug 15. PMID: 22901739
54. Rosenbloom, AL, Rohrs, HJ, **Haller, MJ**, and T Malasanos. Tanner Stage 4 Breast Development in Adults: Forensic Implications. *Pediatrics*. 2012 Oct;130(4):e978-81. doi: 10.1542/peds.2011-3122. Epub 2012 Sep 3. PMID: 22945406
 55. Gan MJ, Albanese-O'Neill A, Haller MJ Type 1 Diabetes: Current concepts in Epidemiology, Pathophysiology, Clinical Care, and Research. *Curr Probl Pediatr Adolesc Health Care*. 2012, Nov-Dec 42(10):269-91. PMID: 23046732
 56. Miller KM, Beck RW, Bergenstal RM, Goland RS, **Haller MJ**, McGill JB, Rodriguez H, Simmons JH, Hirsch IB;T1D exchange clinic network. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D Exchange clinic registry participants. *Diabetes Care* 2013 Jul;36(7):2009-14. doi: 10.2337/dc12-1770. Epub 2013 Feb 1. PMID:23378621 PMCID: PMC3687326
 57. **Haller MJ**, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA. Autologous Umbilical Cord Blood Infusion Followed by Oral Docosahexanoic Acid and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 Diabetes. *Biol Blood Marrow Transplant*. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20. PMID: 23611977 PMCID: PMC3852705
 58. Rohrs, HJ, **Haller, MJ**. Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) Syndrome. First Consult, MD Consult Web site. http://www.mdconsult.com/das/pdxmd/body/415317270-2/0?type=med&eid=9-u1.0-_1_mt_2001352&tab=I. Posted May 3, 2013.
 59. Myhr CB, Hulme MA, Wasserfall CH, Hong PJ, Lakshmi PS, Schatz DA, **Haller MJ**, Brusko TM, Atkinson MA. The autoimmune disease-associated SNP rs917997 of *IL18RAP* controls IFN γ production by PBMC. *J Autoimmun*. 2013 Aug;44:8-12. Doi: 10.1016/j.jaut.2013.06.001 Epub 2013 July 24. PMID: 23891168 PMCID: PMC3775347
 60. Larsson HE, Vehik K, Gesualdo G, Akolkar B, Hagopian W, Krischer J, Lernmark A, Rewers M, Simell O, She, JX, Ziegler, A, **MJ Haller**, TEDDY Study Group. Children Followed in the TEDDY Study are Diagnosed with Type 1 Diabetes at an Early Stage of Disease. *Pediatr Diabetes*. 2014 Mar;15(2):118-26. doi: 10.1111/pedi.12066. Epub 2013 Aug 27. PMID:24034790 PMCID: PMC3866211
 61. Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, **MJ Haller**, Pediatric Diabetes Consortium. Pediatric diabetes consortium T1D new onset (NeOn) study; clinical outcomes during the first year following diagnosis.

- Pediatr Diabetes*. 2014 Jun;15(4):287-93. doi: 10.1111/pedi.12068. Epub 2013 Aug 15. PMID: 23944865 PMCID:PMC3844085
62. Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D, Atkinson M, **Haller MJ**, Egger D, Burdach S, Ziegler AG. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial. *Pediatr Diabetes*. 2014 Mar;15(2):100-9 doi:10.1111/pedi.12072.Epub 2013 Sep 19 PMID:24102806
 63. Rohrs HJ 3rd, Silverstein JS, Weinstein DA, Amdur RJ, **MJ Haller**. Thyroid Storm Following Radioactive Iodine (RAI) Therapy for Pediatric Graves Disease. *Am J Case Rep* 2014 May 14;15:212-5 doi: 10.12659/AJCR.890366. eCollection 2014. PMID: 24847412 PMCID: PMC4026146
 64. Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors (**MJ Haller** T1D Sourcebook Author). Type 1 diabetes through the life span: a position statement of the American Diabetes Association. *Diabetes Care* 2014 Jul;37(7):2034-54. doi: 10.2337/dc14-1140 PMID: 24935775
 65. Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, **Haller MJ**;for the T1D exchange clinic network. Therapeutic Inertia: Underdiagnosed and Undertreated Hypertension (HTN) in Children Participating in the T1D Exchange Clinic Registry. *Pediatr Diabetes* 2014 Oct 21. doi: 10.1111/pedi.12231. [Epub ahead of print]. PMID: 25330905
 66. Couper JJ, **Haller MJ**, Ziegler AG, Knip M, Ludvigsson J, Craig ME. Phases of type 1 diabetes in children and adolescents. *Pediatr Diabetes*. 2014 Sep;15 Suppl 20:18-25. PMID:25325095
 67. Davis AK, DuBose SN, **Haller MJ**, Miller KM, DiMeglio La, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ,;T1D exchange network. Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes. *Diabetes Care*. 2015 Mar;38(3):476-81. doi: 10.2337/dc14-1952. Epub 2014 Dec 17. PubMed PMID: 25519448
 68. **Haller MJ**, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, SchatzDA. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. *J Clin Invest*. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15. PMID: 25500887
 69. Xue S, Posgai A, Wasserfall C, Campbell-Thompson M, Mathews C, Rabinovitch A, Savinov A, Battaglia M, Schatz D, **Haller MJ**, Atkinson M. Combination therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. *Diabetes*. 2015. July 16. E-pub. PMID: 26185279

70. Mathews, C, Xue, S, Posgai, A, Lightfood, Y, Xie, L, Wasserfall, C, **Haller, MJ**, Schatz, D, and MA Atkinson. Accute versus progressive onset of diabetes in NOD Mice- Potential Implications for Therapeutic Interventions in Type 1 Diabetes. *Diabetes*. 2015 Jul 27 PMID: 26216853
71. Campbell-Thompson ML, Kaddis JS, Wasserfall C, **Haller MJ**, Pugliese A, Schatz DA, Shuster JJ, Atkinson MA. The influence of type 1 diabetes on relative pancreas weight. *Diabetologia*. 2015 Sept 10 E-pub. PMID: 26358584
72. **Haller, MJ**, Atkinson M, Wasserfall C, Brusko T, Mathews C, Hulme M, Cintron M, Shuster J, McGrail K, Posgai A, and DA Schatz. Mobilization Without Immune Depletion Fails to Restore Immunological Tolerance or Preserve Beta Cell Function in Recent Onset Type 1 Diabetes. *Clinical and Experimental Immunology*. E Pub. Oct 2015 PMID: 26462724
73. Meehan C, Fout B, Ashcraft J, Schatz DA, **Haller MJ**. Screening for T1D Risk to Reduce DKA is Not Economically Viable. *Pediatr Diabetes*. 2015 Sep 22. doi: 10.1111/pedi.12313. [Epub ahead of print] PMID: 26392298
74. Beauchamp G, **Haller MJ**. Can We Prevent Type 1 Diabetes? *Curr Diab Rep*. 2015 Nov;15(11):86. doi: 10.1007/s11892-015-0658-6.PMID: 26370697
75. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, **Haller MJ**, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. *Diabetes Care*. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17. PMID: 26681725
76. Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, **Haller MJ**, Raman S, Tamborlane WV, Coffey JK, Saenz AM, Beck RW, Nadeau KJ; T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA*. 2015 Dec 1;314(21):2241-50. doi: 10.1001/jama.2015.16174. PMID: 26624824
77. Meehan, CS, Kethireddy, PL, Ashcraft, JK, Shuster, J, and **MJ Haller**. Pre-Meal Insulin Decreases Arterial Stiffness in Children with Type 1 Diabetes. *Pediatric Diabetes*. In Press, 2016
78. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgard B, Blennow K, Zetterberg H, Spalding K, **Haller MJ**, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Humbert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y. Identification of tissue-specific cell death

- using methylation patterns of circulating DNA. *Proc Natl Acad Sci U S A*. 2016 Mar 14. pii: 201519286. [Epub ahead of print] PMID: 26976580
79. Larsson HE, Vehik K, **Haller MJ**, Liu X, Akolkar B, Hagopian W, Krischer J, Lernmark Å, She JX, Simell O, Toppari J, Ziegler AG, Rewers M; TEDDY study. Growth and risk for islet autoimmunity and progression to type 1 diabetes in early childhood: The Environmental Determinants of Diabetes in the Young Study. *Diabetes*. 2016 Jul;65(7):1988-95 PMID: 26993064
 80. **Haller MJ**, Schatz DA. The DIPP Project: Twenty Years of Discovery in Type 1 Diabetes. *Pediatr Diabetes*. 2016 Jul;17 Suppl 22:5-7 PMID: 27411430
 81. Meehan CS, Kethireddy PL, Ashcraft JK, Shuster JJ, **Haller MJ**. Premeal insulin decreases arterial stiffness in children with type 1 diabetes. *Pediatric Diabetes* 2016 May 13 [Epub ahead of print] PMID: 27174580
 82. Nambam B and **MJ Haller**. Updates on Immune Therapies in Type 1 Diabetes. *European Endocrinology*. 2016; 12(2):89-95
 83. **Haller MJ**, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA, Shuster JJ, Zou B, Wasserfall CH, Posgai A, Mathews CE, Brusko TM, Atkinson MA, Schatz DA. Anti-thymocyte Globulin + G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders with Established Type 1 Diabetes. *Diabetes*. 2016 Sept 26. [Epub ahead of print] PMID: 27669730
 84. Zimmerman C, Guifree, D, and MJ Haller. Diagnossi and Management of New Onset Diabetes for the General Pediatrician. *Journal of the Florida Chapter of the AAP*. In Press, 2016 (Peer Reviewed)
 85. Beauchamp G, Boyle CT, Tamborlane WV, Miller KM, Libman IM, **Haller MJ (Co-Senior Author)**, Beck RW. Treatable diabetic retinopathy is extremely rare amongst pediatric T1D Exchange Registry participants. *Diabetes Care*. DOI:10.2337/dc16-1691 2016. PMID: 27852686
 86. Bonifacio E, Mathieu C, Nepom GT, Ziegler AG, Anhalt H, **Haller MJ**, Harrison LC, Hebrok M, Kushner JA, Norris JM, Peakman M, Powers AG, Todd JA, Atkinson MA. Rebrandin asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. *Diabetologia*. 2016 Oct 26. PMID: 27785529
 87. Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, **Haller MJ**, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. *Diabetes Care* 2016;39:264-270. *Diabetes Care*. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available. PMID:27660135

88. Seay HR, Putnam AL, Cserny J, Posgai AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Lares AP, Brown HL, Brown KS, Balavage KT, Peters L, Bushdorf A, Atkinson MA, Bluestone JA, **Haller MJ**, Brusko TM. Expansion of human Tregs from cryopreserved umbilical cord blood for GMP-comolaint autologous adoptive cell transfer therapy. *Mol Ther Methods Clin Dev.* 2016 Dec 24;4:178-191. doi: 10.1016/j.omtm.2016.12.003. eCollection 2017 Mar 17. PMID:28345003
89. Albanese-O'Neill A, Wu M, Miller KM, Jacobsen L, Haller MJ, Schatz D. Poor adherence to ketone testing in patients with type 1 diabetes. *Diabetes Care.* 2017 Jan 18. pii: dc162620. doi: 10.2337/dc16-2620. [Epub ahead of print] No abstract available. PMID:28100607
90. Li X, Campbell-Thompson M, Wasserfall CH, McGrail K, Posgai A, Schultz AR, Brusko TM, Shuster J, Liang F, Muir A, Schatz D, **Haller MJ**, Atkinson MA. Serum trypsinogen levels in pre-type 1 diabetes. *Diabetes Care.* 2017 Jan 23. Pii:dc161774 doi:10.2337/dc 16-1774 PMID: 28115475
91. Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA, **Haller MJ**, Ahmed S, Akolkar B, Lernmark Å, Rewers MJ, Krischer JP; and the TEDDY Study Group. Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. *Pediatr Diabetes.* 2017 Jan 27. doi: 10.1111/pedi.12485. [Epub ahead of print] PMID: 28127835
92. Lundgren M, Steed LJ, Tamura R, Jonsdottir B, Gesualdo P, Crouch C, Sjöberg M, Hansson G, Hagopian WA, Ziegler AG, Rewers MJ, Lernmark Å, Toppari J, She JX, Akolkar B, Krischer JP, **Haller MJ**, Elding Larsson H; TEDDY Study Group. Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity. *BMC Pediatr.* 2017 May 16;17(1):127. doi: 10.1186/s12887-017-0884-y. PMID: 28511706
93. Marcial GE, Ford AL, **Haller MJ**, Gezan SA, Harrison NA, Cai D, Meyer JL, PerryDJ, Atkinson MA, Wasserfall CH, Garrett T, Gonzalez CF, Brusko TM, Dahl WJ, Lorca GL. *Lactobacillus johnsonii* N6.2 modulates the host immune responses: a double-blind, randomized trial in healthy adults. *Front Immunol.* 2017 Jun 12;8:655. doi: 10.3389/fimmu.2017.00655. eCollection 2017. PMID: 28659913
94. Jacobsen LM, **Haller MJ**, Parish A, Gurka MJ, Levine R, Wasserfall C, Campbell-Thompson M, Kaddis J, Pugliee A, Atkinson MA, Schatz DA. High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. *Diabetes Care.* 2017 Jul 5. pii: dc170996. doi: 10.2337/dc17-0996. [Epub ahead of print] No abstract available. PMID: 28679687
95. Zimmerman C, Guiffre D, **Haller MJ**. Diagnosis & Management of New Onset Diabetes for the General Pediatrician. *The Florida Pediatrician.* Vol 36, issue 3, 12-16 2017

96. **Haller M**, Schatz D, Atkinson M. More on Intralymphatic Injection of Autoantigen in Type 1 Diabetes. *N Engl J Med*. 2017 Jul 27;377(4):403. doi: 10.1056/NEJMc1703468. No abstract available. PMID:28748691
97. Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Elding Larsson H, Lynch KF, Lönnrot M, **Haller MJ**, Lernmark Å, Hagopian WA, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Rewers MJ, Hyöty H; TEDDY Study Group. *Diabetologia*. 2017 Oct 9. doi: 10.1007/s00125-017-4448-3. [Epub ahead of print] PMID:28990147
98. Lynch KF, Lee HS, Törn C, Vehik K, Krischer JP, Larsson HE, **Haller MJ**, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Hyöty H, Bonifacio E, Lernmark Å; TEDDY Study Group. Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β -cell autoantibodies *J Autoimmun*. 2017 Sep 20. pii: S0896-8411(17)30558-9. doi: 10.1016/j.jaut.2017.09.005. [Epub ahead of print] PMID:28941965
99. Jacobsen LM, Posgai A, Seay HR, **Haller MJ**, Brusko TM. T Cell Receptor Profiling in Type 1 Diabetes. *Curr Diab Rep* (2017) 17:118 DOI 10.1007/s11892-017-0946-4 PMID: 29022222
100. Jacobsen LM, **Haller MJ**. Presymptomatic Screening for Autoimmune β -Cell Disorder (ABCD): Baby Steps Towards Prevention? *Pediatr Diabetes*. 2018 Feb;19(1):11-13. doi: 10.1111/pedi.12620. No abstract available. PMID: 29368416
101. Jacobsen LM, **Haller M**, Schatz DA. Understanding Pre-Type 1 Diabetes: The Key to Prevention. *Front Endocrinol* (Lausanne). 2018 Mar 6;9:70. PMID: 29559955
102. Smith L, Liu X, Johnson SB, Tamura R, Elding LH, Ahmed S, Veijola R, **Haller MJ**, Akolkar B, Hagopian WA, Rewers MJ, Krischer J, Steck AK, TEDDY study group. Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful? *Pediatr Diabetes*. 2018 Mar 26. doi: 10.1111/pedi.12674. [Epub ahead of print] PMID: 29577538
103. Walker AF, Hall JM, Sherkman EA, Gurka MJ, Morris HL, **Haller MJ**, Rohrs HJ, Salazar KR, Schatz DA. Geographic access to endocrinologists for Florida's publicly insured children with diabetes. *Am J Manag Care*. 2018 Mar;24(4 Spec No.):SP106-SP109. No abstract available. PMID: 29689143
104. Smith LB, Liu X, Johnson SB, Tamura R, Larsson HE, Ahmed S, Veijola R, **Haller MJ**, Akolkar B, Hagopian WA, Rewers MJ, Krischer J, Steck AK, The TEDDY study group. Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful? *Pediatric Diabetes*. 26 March 2018 <https://doi.org/10.1111/pedi.12674> PMID: 30012675

105. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA, Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β -Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. *Diabetes Care*. 2018 Jul 16. pii: dc180494. doi: 10.2337/dc18-0494. [Epub ahead of print] PMID: 30012675
106. Albanese-O'Neill, Beauchamp G, Thomas N, Westen S, Johnson N, Schatz D, **Haller MJ**. Transition education for young adults with type 1 diabetes: A pilot study of the feasibility of a group telehealth intervention. *JMIR Diabetes* 2018 Nov 5;3(4):e10909. doi: 10.2196/10909 PMID: 30401674
107. Westen S, **Haller MJ**, Albanese-O'Neill, Warnick JL, Entessari M, Janicke D, Schatz D. Objectively-Measured Adherence in Adolescents with Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy. *J Pediatr Psychol*. 2018 Sep 3. doi: 10.1093/jpepsy/jsy064. [Epub ahead of print] PMID: 30184209
108. Couper JJ, **Haller MJ**, Greenbaum CJ, Ziegler AG, Wherrett DK, Knip M, Craig ISPAD Clinical Practice Consensus Guidelines 2018 Stages of type 1 diabetes in children and adolescents. *ME.Pediatr Diabetes*. 2018 Jul 26. doi: 10.1111/pedi.12734. [Epub ahead of print] PMID: 30051639
109. Jacobsen LM, Newby BN, Perry DJ, Posgai AL, **Haller MJ**, Brusko TM. Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. *Curr Diab Rep*. 2018 Aug 30;18(10):90. doi: 10.1007/s11892-018-1066-5. Review. PMID: 30168021
110. Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH, Gurka MJ, Atkinson MA, Schatz DA, **Haller MJ**. Relative Pancreas Volume is Reduced in First Degree Relatives of Patients with Type 1 Diabetes. *Diabetes Care*. 2018 Dec 14. pii: dc181512. doi: 10.2337/dc18-1512. [Epub ahead of print] PMID:30552130
111. Jacobsen LM, Elding LH, Tamura RN, Vehik D, Clasen J, Sosenko J, Hagopian WA, She JX, Steck AK, Rewers M, Simell O, Toppari J, Veijola R, Ziegler AG, Krischer JP, **Haller MJ**; TEDDY Study Group. Predicting Progression to Type 1 Diabetes from Ages 3 to 6 in Islet Autoantibody Positive TEDDY Children. *Pediatr Diabetes*. 2019 Jan 10. doi: 10.1111/pedi.12812. [Epub ahead of print] PMID: 30628751
112. **Haller MJ**, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE, Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group. Low-dose Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1 Diabetes: Two Year Clinical Trial Data. *Diabetes*. 2019 Jun;68(6):1267-1276. doi: 10.2337/db19-0057. Epub 2019 Apr 9. PMID: 30967424

113. Zimmerman C, Albanese AO, **MJ Haller**. Advances in Type 1 Diabetes Technology over the Last Decade. *Eur Endocrinol*. 2019 Aug;15(2):70-76. doi: 10.17925/EE.2019.15.2.70. Epub 2019 Aug 16. Review. PMID: 31616496
114. Smith MB, Albanese-O'Neill A, Macieira TGR, Yao Y, Abbatematteo J, Lyon D, Wilkie DJ, **Haller MJ**, Keenan G. Human factors associated with CGM use in patients with diabetes: A systematic review. *Diabetes Technol Ther*. 2019 Aug 20. doi: 10.1089/dia.2019.0136. [Epub ahead of print] PMID: 31335196
115. McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, **Haller MJ**, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. *J Diabetes Complications*. 2019 Jun 26. pii: S1056-8727(19)30391-5. doi: 10.1016/j.jdiacomp.2019.06.005. [Epub ahead of print] PMID: 31279735
116. Albanese-O'Neill A, Schatz DA, Thomas N, Bernhardt JM, Cook CL, **Haller MJ**, Bernier AV, Silverstein JH, Westen SC, Elder JH. Designing Online and Mobile Diabetes Education for Fathers of Children With Type 1 Diabetes: Mixed Methods Study. *JMIR Diabetes*. 2019 Aug 6;4(3):e13724. doi: 10.2196/13724. PMID: 31389338
117. Kusmartseva I, Beery M, Hiller H, Padilla M, Selman S, Posgai A, Nick HS, Campbell-Thompson M, Schatz DA **Haller MJ**, Wasserfall CH, Atkinson M. Temporal Analysis of Amylase Expression in Control, Autoantibody Positive, and Type 1 Diabetes Pancreatic Tissues. *Diabetes*. 2019 Oct 9. pii: db190554. doi: 10.2337/db19-0554. [Epub ahead of print]. PMID: 31597639
118. Walker AF, **Haller MJ**, Gurka MJ, Morris H, Bruggeman B, Miller K, Foster N, Anez Zabala C, Schatz DA. Addressing Health Disparities in Type 1 Diabetes through Peer Mentorship. *Pediatr Diabetes*. 2019 Oct 16. doi: 10.1111/pedi.12935. [Epub ahead of print] PMID: 31617648
119. Cuttriss N, **Haller MJ**, Yabut K, Anez-Zabala C, Hood K, Sheehan EP, Basina M, Bernier AV, Baer LG, Filipp S, Chih-Hung JW, Town MA, Gurka M, Maahs D, Walker AF. Primary Care Providers in California and Florida Report Low Confidence in Providing Type 1 Diabetes Care. *Clinical Diabetes*. (In Press)
120. Walker, AF, Atkinson, MA, Brusko, TM, **Haller, MJ**, Schatz, DA. Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers through Undergraduate Research Curriculum. *Medical Science Educator*. (In Press)
121. Shapiro MR, Wasserfall CH, McGrail SM, Posgai AL, Bacher R, Muir A, **Haller MJ**, Schatz DA, Wesley JD, von Herrath M, Hagopian WA, Speake C, Atkinson MA, Brusko TM. Insulin-like growth factor dysregulation both preceding and following Type 1

Diabetes diagnosis. *Diabetes*. 2019 Dec 11. pii: db190942. doi: 10.2337/db19-0942.
[Epub ahead of print] PMID: 31826866

Books, Chapters, and Symposia Proceedings:

1. **Haller MJ** and DA Schatz. Strategies for the Prediction of Type 1 Diabetes. *Clinical Laboratories International*. 27 (4): 8-10, 2003
2. **Haller MJ** and DA Schatz. Diabetes Screening in Children: When and How. *Consultant for Pediatricians*. 4(1):9-10, 2004. *Consultant*. 44(13):1609-1610, 2005
3. **Haller MJ** and DA Schatz. Screening for Metabolic Syndrome in Children. *Consultant for Pediatricians*. 45(6):600-01, 2005.
4. **Haller MJ** and DA Schatz. Screening for the Susceptibility to Type 1 Diabetes. In: *Progress in Diabetes Research*, Ashley Ford (eds), 2005.
5. **Haller MJ**, Atkinson M, and DA Schatz. Type 1 Diabetes Mellitus: Etiology, Presentation and Management. In: *Pediatric Clinics of North America*, Mark Sperling (eds), 52: 1553-1578, 2005.
6. **Haller MJ**, Rosenbloom AR, and JH Silverstein. Type 1 Diabetes in Children and Adolescents. In: *Pediatric Endocrinology*. Fima Lifshitz (eds), Volume 1, 2006.
7. Young BY, Baumgartner, Chen N, Cox C, **Haller MJ**, Hare JM, Harris DT McGuckin CP, Nagler A, and RH Schwarz. Emerging Stem Cell Therapies: The Role of Cord Blood Banks. *OBG Management*. 18(10)S1-16, 2006.
8. Rohrs HJ, Schatz DA, and **MJ Haller**. Current Type 1 Diabetes Prevention and Early Intervention Clinical Trials: Implications for Primary Care Physicians. *Review of Endocrinology*. pg 26-29, October 2007.
9. **Haller MJ**, Rosenbloom AR, and JH Silverstein. Current Strategies in Pediatric Diabetes Management. American Association of Clinical Endocrinology. In: *ASAP Reviews*, Palumbo (eds), December 20, 2007. Available online at ASAP.AACE.com.
10. **Haller MJ**, Winter WE, DA Schatz. Autoimmune Polyglandular Syndromes. In: *Pediatric Endocrinology* (3rd edition). Mark Sperling (eds), Pg 770-787, 2008.
11. Forlenza GF, and **MJ Haller**. Its Summer: Time for Diabetes Camp. *Review of Endocrinology*. 2(7):19-20, 2008
12. **Haller MJ** and DA Schatz. Progress Toward the Prevention and Reversal of Type 1 Diabetes. *House Calls*. Alachua County Medical Society. Fall/Winter, 11-14, 2009.

13. **Haller MJ**, and DA Schatz. Investigational Therapies for Type 1 Diabetes Prevention and Intervention. *Current Diabetes Practice* Volume 9, Issue 1, Pages 6-10. Summer 2010. WWW.CADRE-DIABETES.ORG
14. **Haller MJ**, Atkinson MA, and DA Schatz, editors. Efforts to Prevent and Halt Autoimmune Beta Cell Destruction. In: *Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America*. Elsevier. 39:3; 527-539, 2010. doi:10.1016/j.ecl.2010.05.006. PMID:20723818 PMCID: PMC2925042
15. **Haller MJ**, Rosenbloom AR, and JH Silverstein. Current Strategies in Pediatric Diabetes Management. American Association of Clinical Endocrinology. In: American College of Endocrinology (ACE) Self Assessment Program [online]. 2011. Available at: <http://asap.ace.com>.
16. Chiang JL, **Haller MJ**, and DA Schatz. Update on Global Intervention Studies in Type 1 Diabetes. *Endocrinology and Metabolism Clinics*. Editor: Robert Rapaport. Elsevier. 2012, Dec, 41(4)695-712. PMID: 23099265
17. **Haller MJ**. Type 1 Diabetes in the 21st Century: A review of the landscape. *T1D Sourcebook*, 2013. ADA Press.
18. **Haller MJ**, Winter WE, Schatz DA. Autoimmune polyglandular syndromes. Sperling 9781455748587 Chapter 20 (in press)
19. **Haller MJ**, Rosenbloom AR, and JH Silverstein. Current Strategies in Pediatric Diabetes Management. American College of Endocrinology Self-Assessment Program (ASAP) 2014. Available at: <https://education.ace.com>. Accessibility verified November 12, 2014.
20. **Haller, MJ** High-dose oral insulin may prevent type 1 diabetes in high risk children (editorial). *Endocrine Today*. Vol 13, No 6, Page 20, June 2015

Books Edited:

1. **Haller MJ**, Atkinson MA, and DA Schatz, editors. *Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America*. Elsevier. 39:3, September, 2010

Abstracts (papers presented indicated by asterisk)

- *1. **Haller MJ**, Stalvey MS, and JH Silverstein. Predictors of Metabolic Control: Monitoring May Be the Key. *Pediatric Research*, Vol 53, No 4, 131A-132A, 2003. PAS Seattle, Wa 2003 Poster.
- *2. **Haller MJ**, Samyn MM Nichols WW, Brusko T, Wasserfall C, Schwartz RF, Atkinson M, Shuster JJ, Pierce G, and JH Silverstein. Radial Artery Tonometry as a Marker of

- Endothelial Dysfunction in Children with Type 1 Diabetes. 64th ADA Session, Orlando, FL June 5, 2004. Poster.
- *3. **Haller MJ**, Cooper SC, Brusko T, Putnam A, Freed B, Claire-Salzler M, Atkinson M, Chase P, Ramiya VJ and DA Schatz. Autologous Cord Blood Transfusion Associated with Prolonged Honeymoon in a Child with Type 1 Diabetes. *Diabetes*. Vol 54 (suppl 1), A485, 2005. 65th ADA 2005, San Diego, June 12th, 2005. Poster.
 - *4. **Haller MJ**, Valladares A, and JH Silverstein. 1 Year Follow up of Arterial Stiffness in Children with T1DM. *Diabetes*. Vol 54 (suppl 1) A164, 2005. 65th ADA, San Diego, FL, June 11th, 2005. Poster.
 - *5. Veiner HL, **Haller MJ**, Schatz DA, Ramiya DS. Differentiation of a Human Exocrine Pancreatic Duct-Derived Cell Line in to Insulin-Expressing Cells. *Diabetes*. Vol 54 (suppl 1) A653, 2005. 65th ADA, San Diego, FL, June 11th, 2005. Poster. PAS, Washington DC, May 15, 2005. Oral.
 - *6. **Haller MJ**, Seldona R, Veiner HL, Schatz DA, and VJ Ramiya. Cyclopamine Represses the Sonic Hedgehog Gene and Induces Differentiation of Insulin-Expressing Cells from Mouse Embryonic Stem (ES) Cells. 2005 PAS, Washington DC, May 15, 2005. Oral
 - *7. **Haller MJ**, Stein J, Janus J, Filichia L, Hildebrand K, and J Silverstein. Arterial Stiffness is Increased in Overweight Children. 2006, ADA, Washington DC. Poster
 - *8. Zineh I, Beitelshees AL, **Haller MJ**. Association between NOS3 polymorphisms and arterial stiffness in children with type 1 diabetes. *Clin Pharmacol Ther* 2007;81(Suppl 1):S15. American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, March 21-24, 2007, Anaheim, CA. Poster
 - *9. **Haller MJ**, Hilla-Lee Viener, Todd Brusko, Clive Wasserfall, Kieran McGrail, Susan Staba, Chris Cogle, Mark Atkinson, and Desmond Schatz, Insulin Requirements, HbA1c, and Stimulated C-Peptide Following Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes. *Diabetes* Vol 56 (suppl 1), A82, 2007. 67th ADA, Chicago, IL, June 25th, 2007. Oral.
 - *10. Hilla-Lee Viener, Todd Brusko, Clive Wasserfall, Kieran McGrail, Susan Staba, Chris Cogle, Mark Atkinson, Desmond Schatz, and **MJ Haller**. Changes in Regulatory T Cells Following Autologous Umbilical Cord Blood Transfusion in Children with Type 1 Diabetes. *Diabetes* Vol 56 (suppl 1), A82, 2007. 67th ADA, Chicago, IL, June 25th, 2007. Oral.
 - *11. Jean Park, Elain Cochran, **MJ Haller**, Desmond Schatz, and Phillip Gorden. "Insulin Resistance and Generalized Lipodystrophy Associated with Type 1 Diabetes: The Response to Leptin Therapy." *Diabetes* Vol 56 (suppl 1), A165, 2007. 67th ADA, Chicago, IL, June 25th, 2007. Poster.

- *12. Song Xue, CH Wasserfall, MJ Parker, KM McGrail, SM McGrail, MC Moore, TM Brusko, DA Schatz, MA Atkinson, and **MJ Haller**. Exenatide Enhances Beta-Cell Mass, Increases Beta-Cell Division, and Decreases Apoptosis But Does Not Reverse Hyperglycemia in New Onset NOD Mice. *Acta Diabetologica*. Vol 44 (suppl 1), A19, 2007. 9th Immunology of Diabetes, Miami, FL, November, 2007. Oral
- *13. Smith L, **Haller MJ**, Staba-Kelly, S. Characteristics and Cell Composition of Privately Banked Autologous Cord Blood (UCB) Units Utilized for Autologous Infusion in Children with Type I Diabetes. CIBMTR/ASBMT Tandem meeting, San Diego, California, February 2008. *Biology of Blood and Marrow Transplant*. Vol 14, issue 2, supplement 1, page 75. Poster
- *14. Wasserfall C, Schatz D, Xue S, Parker M, McGrail S, **Haller M**, and M Atkinson. Combination Therapies for the Reversal of Type 1 Diabetes: the NOD Mouse Model. ISPAD, Durban, South Africa, August 2008. *Pediatric Diabetes*. Vol 9, Suppl 10, Pg 19-20, 2008. Oral
- *15. Meldrum M, Shuster J, Theriaque J, Welder G, **Haller, MJ**, Schofield R, and I Zineh. Atorvastatin differentially affects plasma and leukocyte MCP-1 concentrations from NOS3 gene variation. ASCPT. Washington, DC, March 18-21, 2008. Poster
- *16. Bierschenk L, Alexander J, Wasserfall C, **Haller MJ**, Schatz D, and M Atkinson. An Investigation into Serum Vitamin D and its Carrier Protein in Type 1 Diabetes. Pediatric Science Days. Gainesville, FL. April 24th, 2009. Poster
- *17. Parker M, Xue S, Wasserfall C, Campbell-Thompson M, Schatz D, **Haller MJ**, and MA Atkinson. Reversal of Diabetes and Amelioration of Insulinitis in NOD mice by Combination Therapy of Murine Anti-Thymocyte Globulin and Granulocyte Colony Stimulating Factor. Pediatric Science Days. Gainesville, FL. April 24th, 2009. Poster
- *18. Ramij V, Wasserfall, C, Xue S, Parker M, **Haller MJ**, Schatz DA, and MA Atkinson. Combination Therapy with IL-2 and Rapamycin Reverses Type 1 Diabetes in NOD Mice. Pediatric Science Days. Gainesville, FL. April 24th, 2009. Poster
- *19. Rohrs H, Silverstein JH, **Haller MJ**, and DA Weinstein Thyroid Storm and Seizure in a Pediatric Patient Presenting One Day after Receiving Radioactive Iodine (RAI) Therapy. Endocrine Society, Washington DC, June 10-13, 2009 Poster
- *20. **MJ Haller**, C Wasserfall, K McGrail, HL Viener, M Cintron, S Gaitan, T Brusko, J Wingard, C Cogle, WB Slayton, S Kelly, M Atkinson, DA Schatz. Autologous Umbilical Cord Blood Transfusion in Very Young Children with T1D: 1 Year Follow-up. *Diabetes* 58 (suppl): A7, 2009. Oral
- *21. H Ma, Y Lu, W Li, C Wasserfall, **MJ Haller**, M Campbell,-Thompson, M Brantly, D Schatz, M Atkinson, S Song. Prevention and Reversal of Type 1 Diabetes by Alpha 1

- Antitrypsin (AAT) Given Intradermally in NOD Mice. *Diabetes* 58 (suppl): A50, 2009. Oral
- *22. V Ramiya, C Wasserfall, S Xue, M Parker, **MJ Haller**, D Schatz, M Atkinson. Combination Therapy with IL-2 and Rapamycin Reverses Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice. *Diabetes* 58 (suppl): A87, 2009, Oral.
- *23. Bierschenk L, Alexander J, Wasserfall C, **Haller MJ**, Schatz D, Atkinson M. Suboptimal Vitamin D Levels Are Not Limited to Those with Type 1 Diabetes. *Diabetes* 58 (suppl): A583, 2009, Oral.
- *24. D Ize-Ludlow, Y Luzardo, M Parker, Z Xue, C Wasserfall, **MJ Haller**, D Schatz, M Atkinson, C Mathews. Progressive Erosion of Beta Cell Function Precedes the Onset of T1D in the NOD Mouse. *Diabetes* 58 (suppl): 1245-P, Poster, 2009.
- *25. K Vehik, **MJ Haller**, Ping Xu, DA Schatz, J Krischer, DPT-1 Study Group. Seroconversion in the DPT-1 Study: Evidence of Triggering of Autoimmune Process at Different Ages. EASD Annual Meeting, Vienna, September 29, 2009, Poster
- *26. Blanton D, Bierschenk L, Han Z, Wasserfall C, **Haller MJ**, Schatz D, Atkinson M. Vitamin D Binding Protein Serum Levels and Genotype in Those with Type I Diabetes. Florida Genetics Symposium. Gainesville, FL, October 29, 2009, Poster.
- *27. Vehik K, **Haller MJ**, Schatz DA, Mahon JL, Skyler JS, Sosenko JM, Beam C, and J Krischer. Development of Autoantibodies in the TrialNet Natural History Study (NHS). 213-OR. American Diabetes Association, Orlando, FL June 27, 2010. *Diabetes* 59, (suppl 1): A57, 2010. Oral
- *28. Parker M, Wasserfall C, Xue S, Campbell-Thompson M, Mathews C, Schatz D, **Haller M**, and MA Atkinson. Granulocyte Colony-Stimulating Factor Enhances Both ATG and Anti-CD3 mAb-Mediated Reversal of Type 1 Diabetes in NOD Mice. American Diabetes Association, Orlando, FL June 27, 2010. *Diabetes* 59, (suppl 1): A117, 2010. Poster
- *29. Myhr C, Wasserfall C, **Haller M**, Schatz D, and M Atkinson. Unique Gene Expression Profiles from Peripheral Blood in Subjects with Type 1 Diabetes. American Diabetes Association, Orlando, FL June 27, 2010. *Diabetes* 59, (suppl 1): A331, 2010. Poster
- *30. Atkinson MA, Wasserfall C, Schatz DA, **Haller MJ**, and LR Jebson. To Arrest the Immune Assault on Beta Cells in Vivo. Helmsley Trust Type 1 Diabetes Annual Investigator Meeting. October 9, 2010, NY, NY. Oral.
- *31. **Haller MJ**, Gottleib P, Gitelman S, Schatz DA, and MA Atkinson. Reversing Type 1 Diabetes After it is Established. Helmsley Trust Type 1 Diabetes Annual Investigator Meeting. October 9, 2010, NY, NY. Oral.

- *32. Xue Song, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D, Atkinson M, and **M Haller**. Multi-Drug Combination Therapy Reverses Diabetes in NOD Mice with Established Disease. UF Science Day, College of Medicine, 2011. Oral
- *33. Xue Song, Wasserfall, Brusko T, Mathews, **Haller M**, Burn P, Atkinson M, and D. Schatz Multi-Drug Combination Therapy Increases the Frequency of Regulatory T- and B-Cells in NOD Mice with Established Disease. UF Science Day, College of Medicine, 2011. Oral
- *34. Minarich L and **MJ Haller**. A Case of Transient Neonatal Diabetes and Congenital Diaphragmatic Hernia. ENDO 2011: The 93rd Annual Meeting & Expo, June 4-7 in Boston, Massachusetts. Poster
- *35. Xue S, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D, Atkinson M, **Haller M**. Multi-Drug Combination Therapy Reverses Diabetes in NOD Mice with Established Disease. 71st Scientific Session, San Diego CA, June 2011. *Diabetes 60* (suppl1): A73, 2011. Oral
- *36. Han Z, Whitener R, Atkinson MA, **Haller MJ**, Schatz DA, Bluestone JA, Brusko TM. Generation of antigen-specific regulatory T cells from human umbilical cord blood. *Diabetes 60* (suppl1):A122, San Diego CA, June 2011. Presidents Poster
- *37. Xue S, Wasserfall C, Brusko T, Mathews C, **Haller M**, Burn P, Atkinson M, Schatz D. Multi-drug combination therapy increases the frequency of regulatory T- and B- cells in NOD mice with established disease. *Diabetes 60* (suppl1): A91, San Diego CA, June 2011. Oral
- *38. Myhr C, Wasserfall C, Schatz D, **Haller M**, Atkinson M. Th1 and Th17 associated gene expression profiles in subjects with type 1 diabetes. *Diabetes 60* (suppl1):A397, San Diego CA, June 2011. Poster
- *39. Hulme M, Wasserfall CH, Brusko TM, **Haller MJ**, Schatz DA, Ostrov DA, Atkinson MA. Small molecule modification of the IL-2 receptor: implications for therapy in type 1 diabetes. *Diabetes 60* (suppl1):A401, San Diego CA, June 2011. Poster
- *40. Bode BW, Beck RW, DuBose SN, Peters AL, Hirsch IB, Miller KM for the T1D Exchange Clinic Network. A Comparison of Users and Nonusers of Real-time Continuous Glucose Monitoring (CGM) with Type 1 Diabetes (T1D) in the T1D Exchange. (study group member)
- *41. Wood JA, Kaminski BM, Kollman C, Pediatric Diabetes Consortium. The Accuracy and Precision of the Axis-Shield Afinion HbA1C Measurement Device. *Diabetes 60* (suppl1):A237, San Diego CA, June 2011. Poster

- *42. Cengiz E, Kaminski BM, Klingensmith GJ, Haymond MW, Lee JM, Tamborlane W, Pediatric Diabetes Consortium. New Insights to an Old Disease: Major Clinical Outcomes within First Year of Diagnosis for Youth with Type 1 Diabetes (T1D) from Pediatric Diabetes Consortium (PDC) Cohort. *Diabetes 60* (suppl1):A2334, San Diego CA, June 2011. Poster
- *43. Klingensmith GJ, Kaminski BM, Pediatric Diabetes Consortium. Obesity and DKA Are Common in Youth at T1D Onset: Findings of the Pediatric Diabetes Consortium (PDC). *Diabetes 60* (suppl1):A340, San Diego CA, June 2011. Poster
- *44. T1D Exchange Study Group (Member writing group). BMI in children with autoimmune type 1 diabetes. ISPAD, Miami Beach, Oct 2011. Oral
- *45. PDC (Member Writing Group). Race and socioeconomic status are independent predictors of youth receiving insulin pump therapy in the first year of type 1 diabetes treatment. ISPAD, Miami Beach, Oct 2011. Oral
- *46. **Haller MJ**, Schatz DA, Dennis MA, Cintron M, Jebson LR, Wasserfall C, Gottlieb P, Michels A, Lungaro J, Gitelman SE, Wertz M, and MA Atkinson. Reversing Type 1 Diabetes After It Is Established. Helmsley Investigator Meeting. Chicago, Oct 27-28, 2011, Oral.
- *47. Atkinson MA, Wasserfall C, Schatz D, **Haller MJ**, and LR Jebson. To Arrest The Immune Assault on Beta Cells in Vivo. Helmsley Investigator Meeting. Chicago, Oct 27-28, 2011, Oral.
- *48. Rosenbloom AL, Rohrs HJ, **Haller MJ**, and T Malasanos. Tanner Stage 4 Breast Development in Adults: Forensic Implications. Pediatric Academic Societies' Annual Meeting, April 28-May 1, 2012, in Boston, Massachusetts. Poster
- *49. **MJ Haller**, C Wasserfall, K McGrail, M Cintron, T Brusko, J Wingard, WB Slayton, MA Atkinson, DA Schatz. Pilot Study of Autologous Umbilical Cord Blood (UCB) Transfusion Followed by Docosahexanoic Acid (DHA) and Vitamin D (VitD) Supplementation in Children with Type 1 Diabetes (T1D). American Diabetes Association June 8-12, Philadelphia, PA, 2012. Poster Audio Tour.
- *50. Hulme M, Han Z, Alexander J, Wasserfall C, **Haller M**, Schatz D, Brusko T, Atkinson M. Soluble CD25 Expression in Primary Human CD4+ T Cells Enhances Cellular Expansion and IL-2 Responsiveness. American Diabetes Association June 8-12, Philadelphia, PA, 2012. Poster
- *51. **Haller MJ**, Wasserfall CH, McGrail K, Cintron M, Brusko TM, Slayton W, Clare-Salzler MJ, Wingard JR, Atkinson MA, Schatz DA. Pilot study of autologous umbilical cord blood (UCB) and vitamin D (VitD) supplementation in children with type 1 diabetes (T1D) 72nd ADA Scientific Session, June 2012 Philadelphia PA. Poster

- *52. Dimeglio LA, Miller KM, Beck RW, Buckingham BA, **Haller MJ**, Mehta SN, Nadea K, Ratlif C, Tamborlane WV, T1D Exchange Clinic Network. Most Persons With Type 1 Diabetes (T1D) Do Not Meet Clinical Recommendations: An Anyalysis from the T1D Exchange Clinic Registry. 72nd ADA Scientific Session, June 2012 Philadelphia PA. Poster
- *53. Davis A, **Haller M**, Miller K, DuBose S, Carpenter C, DiMeglio L, Liljenquist D, Ahmann A, Marcovina S, Greenbaum C, Beck R. Residual C-peptide in patients 3-81 years from diagnosis of T1D *Diabetes*. July 2013 vol 62 suppl 1 Page A422-423
- *54. **Haller MJ**, Cintron M, McGrail K, Brusko TM, Wasserfall C, Hulme M, Mathews CE, Atkinson MA, Schatz DA. Granulocyte Colony Stimulating Factor (GCSF) Fails to Preserve Beta-Cell Function in Patients with Recent Onset Type 1 Diabetes (T1D) *Diabetes* June 2014 Vol 63 Suppl 1 pg A428
- * 55. Fuhrman CA, Newby BN, Lakshmi PS, Seay HR, Atkinson MA, Schatz DA, **Haller MJ**, Mathews CE, Brusko TM. IL-12 and IL-18 Potentiate Th1-Immunity and Cytotoxic T Cell-Mediated Killing of Human β ox5 Cells. *Diabetes* June 2014 Vol 63 Suppl 1 Pg A429
- *56. **Haller MJ**, Cengiz E, Tamborlane WV, Roy S, Thambundit A, Beck RW, Kollman G, Ruedy K, Connor C, Buckingham B, Gregg B, Thomas I. Frequency of Self-Monitoring of Blood Glucose (SMBG) and A1C Levels in Youth with Type 2 Diabetes (T2D): Data from the Pediatric Diabetes consortium (PDC) T2D Registry Consortium (PDC) T2D Registry. *Diabetes* June 2014 Vol 63 Suppl 1 Pg 390
- *57. **Haller MJ**, Atkinson MA, Gitelman SE, Gottlieb PA, Michels A, Sanda S, Rosenthal S, Dennis MA, Cintron M, Wesch R, Wertz M, Hulme MA, Lungaro J, Brusko TM, Mathews CE, Wasserfall C, Schatz DA. Combination Low-Dose Antithymocyte Globulin (ATG) and Granulocyte Colony Stimulating Factor (GCSF) Preserves Beta-Cell Function in Patients with Established Type 1 Diabetes (T1D) *Diabetes* June 2014 Vol 63 Suppl 1 Pg 39
- *58. Livman I, Miller K, DiMeglio L, Bethin K, Katz M, Shah A, Simmons J, **Haller M**, Raman S, Tamborlane W, Coffey J, Saenz A, Beck R, Nadeau K. "The Metformin As an Adjunct Therapy Does Not Improve Glycemic control Among Overweight Adolescents with type 1 Diabetes (T1D). Endo 3/5/2015, San Diego
- *59. Nadeau K, Miller K, DiMeglio L, Bethin K, Katz M, Shah A, Simmons J, **Haller M**, Raman S, Tamborlane W, Coffey J, Saenz A, Beck R, Libman I. The Effect of Metformin on Cardiovascular Risk Factors in Overweight and Obese Adolescents with Type 1 Diabetes. ADA 6/5/15 Boston, MA
- *60. **Haller MJ**, Nambam B, Schatz DA, Shuster JJ, Williams JJ, Beegle R, Cintron M, Ferguson J, Atkinson MA, Campbell-Thompson M. Are Pancreatic Volume and Serum Trypsinogen Markers of Type 1 Diabetes Progression? A preliminary report. IDS 2015-International Diabetes Society 14th International Congress, Munich Germany. Poster

- *61. Seay HR, Balavage KT, Putnam AL, Rosenau EH, Wingard JR, Girard KF, Kraus M, Bluestone JA, **Haller MJ**, Brusko TM. A GMP Compatible Protocol For The Ex Vivo Expansion of Human Regulatory T cells from Cryopreserved Umbilical Cord Blood. 13th International Cord Blood Symposium. San Francisco, CA June 2015. Poster
- *62. Nambam B, Haller MJ, Schatz DA, Shuster JJ, Williams JJ, Beegle R, Cintron M, Ferguson J, Atkinson MA, Campbell-Thompson M. Is pancreas volume a marker of type 1 diabetes progression? A preliminary report. ADA 75th Scientific Session, Boston MA June 2015. Poster
- *63. Nadeau KJ, Miller KM, Dimeglio LA, Bethin KE, Katz ML, Shah AV, Simmon JH, Haller MJ, Raman S, Tamborlane WV, Coffey J, Sanenz LM, Beck RW, Libman IM. Effect of metformin on cardiovascular risk factors in overweight and obese adolescents with type 1 diabetes. ADA 75th Scientific Session, Boston MA June 2015. Poster
- *64. Meehan C, Kethireddy P, Ashcraft J, Haller MJ. Premeal Insulin Mitigates Acute Excursions in Radial Artery Stiffness in Children with Type 1 Diabetes. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *65. Smith LB, Lu X, Vehik K, Driscoll KA, Butterworth M, Baxter J, Ahmed S, Larrson HE, Veijola R, Haller MJ, Krischer JP, Akolkar B, Hagopian WA, Rewers M, Steck A. Psychological Impact of Type 1 Diabetes Diagnosis in children Enrolled in the Prospective TEDDY Study Compared with Those in the Community. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *66. Walker AF, Bell RA, Morris HL, Haller MJ, Shuster J, Shenkman B, Sun Y, Schatz D. Healthcare utilization for publicly insure children with Type 1 Diabetes in Florida and Texas. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *67. Beauchamp G, Boyle CT, Tamborlane WV, Miller KM, De Gordon IL, Beck RW, Haller MJ. Pediatric Diabetic Retinopathy is Extremely Rare Amongst Type 1 Diabetes Exchange Registry Participants. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *68. Jacobsen L, Haller MJ, Kaddis J, Wasserfall C, Levine RS, Campbell-Thompson M, Pugliese A, Atkinson MA, Schatz D. Causes of Death in the First 100 Type 1 Diabetes (T1D) Donors in the Network for Pancreatic Organ Donors with Diabetes (nPOD) ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *69. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Baiming Z, Brusko TM, Hulme M, Wasserfall CH, Perry D, Mathews CE, Atkinson MA, Schatz DA. Combination therapy with ATG + GCSF in established type 1 diabetes: two-year outcomes. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster

- *70. Lin A, Haller MJ, Atkinson MA, Mcgrail K, Schatz D, Brantly M, Mathews CE. Type 1 diabetes results in changes in neutrophils, but not neutrophilic enzymes. ADA 76th Scientific Session, New Orleans, LA June 2016. Poster
- *71. Albanese-O'Neill A, Haller MJ, Bernier A, Schatz D. Mobile diabetes education for fathers of youth with type 1 diabetes: mDAD ADA 77th Scientific Session, San Diego CA, June 2017. Oral
- *72. Westen SC, Sanders K, Warnick J, Gillen S, Albanese-O'Neill A, Haller MJ, Schatz D, Janicke D. Parent fear of hypoglycemia predicts frequency of adolescent blood glucose monitoring. ADA 77th Scientific Session, San Diego CA, June 2017. Poster
- *73. Walker AF, Schatz D, Rohrs H, Weinbrenner D, Shenkman E, Salazar K, Haller MJ. Assessing the needs of publicly insured children with type 1 and type 2 diabetes in primary care settings. ADA 77th Scientific Session, San Diego CA, June 2017. Poster
- *74. Shapiro ER, Wasserfall CH, McGrail SM, Haller MJ, Schatz DA, Atkinson MA, Brusko TM. Diminished insulin-like growth factors in pre-type 1 diabetes. ADA 77th Scientific Session, San Diego CA, June 2017. Poster
- *75. Lin A, Posgai A, Chernatynskaya AV, Hull M, Brusko TM, Atkinson MA, Haller MJ, Mathews CE. Mechanisms of type 1 diabetes prevention by antihymocyte globulin. ADA 77th Scientific Session, San Diego CA, June 2017. Oral
- *76. Jacobsen LM, Schatz DA, Filipp SL, Gurka MJ, Haller MJ, Atkinson MA, Campbell-Thompson M. Islet autoantibodies are associated with insulinitis but not beta cell loss in type 1 diabetes. ADA 77th Scientific Session, San Diego CA, June 2017. Oral
- *77. Albanese-O'Neill, Beauchamp G, Thomas N, Schatz D, Haller MJ. Diabetes education for young adults via telehealth is highly feasible. ICHP Research Day. April 2017. Poster
- *78. Albanese-O'Neill A, Westen SC, Thomas NT, **Haller MJ**, Schatz D. It was all trial and error-The perspective of parents of emerging adults with type 1 diabetes during the transition to independence. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *79. Walker AF, Johnson C, Anez-Zabala C, Dorvil SR, **Haller MJ**, Gurka MJ, Bruggeman BS, Guiffre D, Atkinson MA, Schatz I, Schatz D. Content analysis of text messages in a type 1 diabetes peer mentoring program – the importance of shared interests. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *80. Warnick J, Westen SC, Albanese-O'Neill A, Schatz, D, **Haller MJ**, Janicke D. Examination of accuracy of self-reported blood glucose using mHealth data collection. ADA 78th Scientific Session, Orlando FL June 2018. Poster

- *81. Westen SC, Warnick J, Entessari M, Albanese-O'Neill A, Schatz D, **Haller MJ**, Janicke DM. Poor adherence in adolescents with Type 1 diabetes associated with distress, fear of hypoglycemia, and executive functioning. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *82. Walker AF, **Haller MJ**, Gurka MJ, Morris HL, Anez-Zabala C, Bruggeman BS, Guiffre D, Rohrs III H, Atkinson MA, Schatz D. Promoting health equity in type 1 diabetes through peer mentorship-finding from the ALL for One randomized controlled trial. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *83. Wood J, Boyle C, Qyinn M, Wong JC, **Haller MJ**, Nelson BA, Schatz D, Tamborlane WV, Fox L, Prahalad P, Corathers S, Maahs DM, Alonso GT, Desalvo DJ, Wadwa RP, Dimeglio L. Impact of target HbA1c change in pediatric participants in the T1D exchange clinic registry. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *84. Ross Jj, Wasserfall C, Perry DJ, McGrail KM, Posgai AL, Brusko TM, Schatz D, **Haller MJ**, Atkinson MA. Exocrine pancreatic function as a novel biomarker in pre-T1D. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *85. Thompson-Cambell M, Atkinson MA, Flipp SL, Gurka MJ, Beegle R, Schatz D. **Haller MJ**, Type 1 Diabetes Study Group. Relative pancreas volume is reduced in autoantibody negative first-degree relatives and subjects with pre-type 1 diabetes. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *86. Shapiro M, Wasserfall C, Schultz AR, McGrail SM, **Haller MJ**, Schatz D, Atkinson MA, Brusko TM. Insulin-like growth-factor axis collectively identifies pre-type 1 diabetes. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *87. McGill JB, Wu M, Pop-Bushui R, Stout M, Tamborlane WV, Aleppo G, Gubitosi-Klug R, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Risk factors for adverse kidney disease outcomes in type 1 diabetes (T1D). ADA 78th Scientific Session, Orlando FL June 2018. Poster
- *88. Killian M, Vehik K, Little RR, Larson HE, Haller MJ, Rewers M, She J, Toppari J, Akolkar B, Krischer J, Hagopian W, TEDDY Study Group. Quarterly HbA1c surveillance in children with islet antibodies (IA) accurately predicts type 1 diabetes (T1D) timing. ADA 78th Scientific Session, Orlando FL June 2018. Poster
- 89. Balzano L, Ramirez R, Zamkovaya T, Daley J, Ardisson A, Chamala S, Schatz D, Atkinson M, Haller M, Concannon P, Triplett E, Conesa A. Multiblock integration of transcriptomics and metabolomics to study Type 1 Diabetes progression. Poster PSGDREAM2018

- *90. Cuttriss N, Walker A, Maahs D, Haller M, Anez-Zabala C, Yabut K, Hu H, Filipp S. Democratizing Type 1 Diabetes (T1D) Knowledge in Rural and Underserved Communities: Project ECHO T1D. ATTD February 2019 Berlin Germany. Poster
91. Smith M.B, Albanese-O’Neill A, Macieira TGR, Abbatematteo J, Yao Y, Lyon D, Wilkie DJ, **Haller MJ**, Keenan GM. Human factors associated with CGM use in patients with diabetes: A systematic review. *Diabetes Technology and Therapeutics* (in press)
92. Reynolds CM, Warnick J, Albanese-O’Neill A, Schatz D, **Haller M**, Janicke D M, Westen S. (2019). Diabetes Distress Mediates a Relationship between Executive Functioning and Disordered Eating in Adolescents with Type 1 Diabetes. 2019 Society of Pediatric Psychology Annual Conference, New Orleans, LA. Poster
93. **Haller MJ**, Greco MN, Schatz D, Atkinson MA, Brusko TM, Mathews CE, Jacobsen LM, Herold KC, Gitelman SE, Krischer J, Bundy BN. “Efficacy of New-Onset Type 1 Diabetes (T1D) Intervention Trials: Variation in 1-Year Outcomes. ADA 79th Scientific Session, San Francisco, CA, June 2019. Oral
94. Steck An, Liu X, Krischer J, **Haller MJ**, Veijola R, Akolkar B, Toppari J, Hagopian W, Rewers M, Elding H. “Factors Associated with Decline of C-Peptide in a Cohort of Young Children Diagnosed with Type 1 Diabetes. ADA 79th Scientific Session, San Francisco, CA, June 2019. Oral
95. Cuttriss N, Anez-Zabala C, Baer LG, Bernier A, Basina M, Filipp SL, Hood KK, Gurka MJ, Lal R, **Haller MJ**, Maahs DM, Hu Hui, Town M, Sheehan EC, Wang J, Yabut K, Walker AF, for the ECHO T1D Study. “Leveraging the Project ECHO Model for Type 1 Diabetes (T1D) in California and Florida: Democratizing Knowledge in Underserved T1D Communities”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Oral
96. Albanese-O’Neill A, Macinnes JW, Thomas NT, **Haller MJ**, Schatz D, Silverstein J, Adams J, Oyetero R, Kershaw BA, Anderson K, Bernier A. “Validation of a Clinically Relevant Knowledge Assessment in Pediatric Type 1 diabetes”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Poster
97. Westen SC, Anderson LM, Barry SA, Look S, Pinto S, Albanese-O’Neill A, Kemp CA, **Haller MJ**, Papadakis JL, Schatz D, Olsen BT, Janicke DM, Weissberg-Benchell J, Johnson N. “Barriers and Facilitators of Participation in Clinical Trials among Youth and Young Adults with Type 1 Diabetes and Their Caregivers”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Poster
98. Walker AF, Cuttriss N, **Haller MJ**, Yabut K, Anez-Zabala C, Lal R, Sheehan E, Basina M, Hood KK, Bernier A, Baer LG, Filipp SL, Wang J, Town M, Gurka MJ, Maahs DM. “The Paradox of Cre Delivery for Type 1 Diabetes in Primary Care Settings: A Call for

Interventions to Reduce Health Disparities”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Poster

99. Walker AF, Hu H, Cuttriss N, **Haller MJ**, CJ Wang, Anez-Zabala C, Yabut K, Gurka MJ, Maahs DM. “The Neighborhood Deprivation Index and Provider Geocoding Identify Critical Catchment Areas for Diabetes Outreach Programs”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Poster
100. Ismail HM, Bundy BN, Atkinson MA, Moore MV, **Haller MJ**, Russell WE, Gietlman SE, Herold KC, Redondo MJ, Sosenko JM. “Assessments of Alternative C-Peptide (C-P) Endpoints for New-Onset Type 1 Diabetes (T1D) Clinical Trials”. ADA 79th Scientific Session, San Francisco, CA, June 2019. Poster
101. Ding K, Albanese-O’Neill A, Schatz D, **Haller M**, Janicke DM, Westen SC. Fear of Hypoglycemia Mediates a Relationship between Psychosocial Barriers and Negative Affect towards Adherence in Adolescents with Type 1 Diabetes. Poster Annual Convention of the American Psychological Association, Washington DC. August 2020

LECTURES PRESENTED AT PROFESSIONAL MEETINGS (since 2003)

Local (Invited):

“Parathyroid Adenomas and Hypercalcemia” Grand Rounds, University of Florida, Feb 2003.

“Endocrine Complications of Cancer Therapy in Childhood” Grand Rounds, University of Florida, Feb 3, 2006

“Diabetic Ketoacidosis” Resident Core Conference, University of Florida, October, 2006

“Type 1 Diabetes: From Mouse to Man” Bench To Bedside Conference, University of Florida, October 3, 2007

“Cellular Therapy For Type 1 Diabetes” IDP Program Class Lecture, University of Florida, April 2, 2008

“Combination Therapies to Induce Tolerance in T1D” Pathology, Immunology Research Seminar, University of Florida, October 29, 2008

“Combination Therapies to Induce Tolerance in T1D: Mouse to Man” Pediatrics Research Seminar Series, University of Florida, March 27, 2009

“Cellular Therapy for Type 1 Diabetes” IDP Program Class Lecture, University of Florida, March 30, 2009

“DKA and HHS Emergencies” Second Year Clinical Diagnosis Lecture Series, University of Florida, April 6, 2009

“Delayed and Precocious Puberty” Adult Endocrinology Fellow Lecture Series, University of Florida, April 9, 2009

“Update on DKA Management” Pediatric Residency Core Lecture Series, University of Florida, July 30, 2009

“Immunopathogenesis of Type 1 Diabetes” Pediatric Endocrinology Core Conference, University of Florida, October 2, 2009

“Transition to Adult Care” Gainesville Area Diabetes Educators, University of Florida May 24, 2010

“Stem Cell Research” City of Gainesville ProClub, Martin Luther King Center, Gainesville, Florida, June 30, 2010

“Translational Research” NIH Summer Program for Teachers, University of Florida, July 1, 2010

“Pediatric DKA Management” , UF Emergency Department Grand Rounds, January 27, 2011
“How to Reduce DKA in Type 1 Diabetes” UF Diabetes Center Lectures Series, WebEx Lecture, Oct 13, 2012

“Combination therapy to Reverse Type 1 Diabetes” UF Pediatrics Grand Rounds, May 9, 2013

“Combination therapy to Reverse Type 1 Diabetes” Texas Children’s Grand Rounds March 2015

“Combination therapy in T1D” , Mt. Sinai Endocrine Rounds, NY, NY, September, 2015

“ATG, GCSF, and Oral Insulin” Diabetes Institute Data Club, November 9, 2015

“Update on T1D Management” World Diabetes Day, JDRF, Sarasota, FL, November 14, 2015

“Research Update in T1D” Help a Diabetic Child / YMCA opening, Naples, FL, Nov 15, 2015

“Lessons Learned from 20 Years of Trying to Cure T1D” – Grand Rounds, Pediatric Science Day Visiting Professor, University of Alabama, Birmingham, April 2017

“Combination therapy for T1D” – Endocrine Grand Rounds, Riley Children’s Hospital, Indiana University, Indianapolis, Indiana, May 10, 2017

Regional (Invited):

“Vascular function in children with diabetes” Southern Pediatric Endocrine Society, St. Augustine, Fl, Oct 2005

“Update on DKA Management” Grand Rounds, Monroe Regional Medical Center, January 24, 2008

“Type 1 Diabetes Research” Camp JADA Guest Speaker Series, Jacksonville, FL, June 25, 2009

“Combination therapy to Reverse Type 1 Diabetes” Tampa Bay Diabetes Society, Tampa Bay, FL, August 23, 2012

"What's New in T1D Management" AAP Annual Conference, Orlando, Florida, November 3, 2018

National (Invited):

“Future of Cord Blood Therapy in Type 1 Diabetes” Cord Blood Registry Advisory Meeting, Tucson, Az April 6, 2006.

“Cord blood as immunotherapy for Type 1 Diabetes” JDRF Autoimmunity Center Meeting, Harvard University, Boston, MA, March 19, 2007

“Clinical Studies on the Therapeutic Value of Adult Human Stem Cells” New York Academy of Sciences, NY, NY, September 25, 2007.

“Combination Therapies for Type 1 Diabetes” Immune Tolerance Network Investigator Meeting, San Francisco, California, June 10, 2008

“Cord Blood Immunotherapies for Type 1 Diabetes: Project 1 Update” JDRF Autoimmunity Center Meeting, Harvard University, Boston, MA, August 27, 2008.

“Cord Blood Immunotherapy for T1D: Lessons Learned and a Path Forward” 10th Annual UCB Symposium. San Francisco, June 8, 2012. (Invited but speaking at ADA).

"ATG/GCSF in New Onset T1D: Pathways Towards the Use of Human ATG" Sanford Health Diabetes Symposium Sioux Falls, S.D. November 12th, 2018

“Efficacy of New-Onset Type 1 Diabetes (T1D) Intervention Trials: Variation in 1-Year Outcomes” ADA 79th Scientific Session, San Francisco, CA, June 9, 2019.

“Factors Associated with Decline of C-Peptide in a Cohort of Young Children Diagnosed with Type 1 Diabetes” ADA 79th Scientific Session, San Francisco, CA, June 9, 2019.

“Leveraging the Project ECHO Model for Type 1 Diabetes (T1D) in California and Florida: Democratizing Knowledge in Underserved T1D Communities”. ADA 79th Scientific Session, San Francisco, CA, June 9, 2019.

International (Invited):

“Cord Blood Infusion in Type 1 Diabetes” International Tissue Engineering Research Association (ITERA) Life Sciences Forum, Maastricht, Netherlands, October 24-27th, 2007.

“Autologous Cord Blood Infusion as Immunotherapy for Type 1 Diabetes” 9th Annual Immunology of Diabetes Meeting, Miami, FL November 16th, 2007.

“Cord Blood Immunotherapy in Type 1 Diabetes” 8th Annual Rachmiel Levine Diabetes Symposium, Los Angeles, California, January 16, 2008.

“Cell Therapies for Type 1 Diabetes” American Diabetes Association Scientific Sessions, San Francisco, California, June 7, 2008

“DKA Incidence in New Onset T1D Subjects followed in TEDDY” TEDDY EEC Meeting, Bethesda, MD, December 8, 2008.

“Autologous Cord Blood Infusion: Immunotherapy for Type 1 Diabetes?” American Association of Blood Banks International Meeting, New Orleans, LA, October 26, 2009.

“Rates of Antibody Positivity and DKA in TEDDY Cohort” TEDDY EEC Meeting, Bethesda, MD, December 4, 2009

“Autologous Cord Blood Infusion for Type 1 Diabetes” 7th Annual Asia Pacific Cord Blood Bank Consortium Meeting, Bangkok, Thailand, December 11, 2009.

“Autologous Cord Blood Infusion in Type 1 Diabetes” 8th Annual International Umbilical Cord Blood Transplantation Symposium, San Francisco, CA. June 3-6 2010. (Invited to speak but unable to attend due to prior commitments.)

“Stem Cell Therapies for Type 1 Diabetes” 3rd Annual Diabetes Profession Development Day. McMaster University, Toronto, Canada, May 29, 2010

“Cell Therapies for the Reversal of Type 1 Diabetes” ISPAD Young Investigator Award Speech. Buenos Aires, Argentina, October, 2010

“TEDDY Participation Reduces DKA”, International Society of Pediatric and Adolescent Diabetes, Annual Meeting, Miami, Florida, December 2011

“Immune Therapies in Type 1 Diabetes”, 10th Congresso Paulista de Endocrinologia e Metabologia, Sao Paulo, Brazil, May 16, 2013

“Cord Blood Therapy for T1D: Use of a precious resource” 10th Congresso Paulista de Endocrinologia e Metabologia, Sao Paulo, Brazil, May 16, 2013

“ATG and GCSF for T1D” American Diabetes Association, Chicago, Illinois, June 2013

“Combination Therapies for T1D” ISPAD Science School, Sydney Australia, July 2013

“Novel Therapies for T1D Reversal” Australian Pediatric Endocrine Group, Sydney Australia, July 2013

“ATG/GCSF Therapy for New Onset T1D: Mechanistic Insights and Longer Term Outcomes Immunology of Diabetes Society Annual Meeting, London, England October 28, 2018

“ATG preserves beta cell function in early T1D”, 2019 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium. Pasadena, CA April 2019

Appendix:

Presentations and Publications as a member of the DPT-1, TrialNet (2007-Present), TEDDY (2009-present) PDC, and T1DExchange study groups (2011-Present).

The Environmental Determinants of Diabetes in Youth (TEDDY)

Presentations:

1. At-risk for Type 1 Diabetes (T1D): Parent Anxiety in Response to Newborn Genetic Screening Results in The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Johnson SB, Lernmark B, Baxter J, Roth R, Simell T, McLeod W and the TEDDY group Local Affiliation: The Barbara Davis Center and the Dept. of Preventive Medicine and Biometrics for the TEDDY Study Group, 25th Annual Epidemiologic Research Exchange, Denver, CO, USA: March 2007.
2. Achieving Standardized Medication Data in Clinical Research Studies: Two Approaches and Applications for Implementing RxNorm, Richesson RL, Smith S, Malloy J, Krischer J for the TEDDY Study Group, 2007 American Medical Informatics Association Spring Congress, Orlando, FL, USA: May 2007.
3. At-risk for Type 1 Diabetes (T1D): Parent Anxiety in Response to Newborn Genetic Screening Results in The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Roth R, Johnson SB, Lernmark B, Baxter J, Simell T, McLeod W for the TEDDY Study Group, German Diabetes Association, abstract included in *Diabetologie & Stoffwechsel* 2:71, Hamburg, Germany: May 2007.
4. Infant Feeding Practices in the TEDDY (The Environmental Determinants of Diabetes in the Young) Study, Winkler C for the TEDDY Study Group, German Diabetes Association, Hamburg, Germany: May 2007.
5. Relevant Risk Factors for Type 1 Diabetes – Differences within the TEDDY Study, Koenig S for the TEDDY Study Group, German Diabetes Association, Hamburg, Germany: May 2007.
6. Major Ethnic Differences in HLA-DR-DQ Contribution to the Type 1 Diabetes (T1D) Risk Pool in The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Hagopian W, Rewers M, Lernmark Å, She JX, Erlich H, Peng H, Huang YH, Emery L for the TEDDY Study Group, Annual meeting of the American Diabetes Association, Chicago, IL, USA: June 2007.
7. Major Inter-population Differences in Genetic Susceptibility and Candidate Environmental Risk Factors for Type 1 Diabetes, Rewers M for the TEDDY Study Group, Annual meeting of the American Diabetes Association, Chicago, IL, USA: June 2007.

8. At-risk for Type 1 Diabetes (T1D): Parent Anxiety in Response to Newborn Genetic Screening Results in The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Johnson SB, Lernmark B, Baxter J, Roth R, Simell T, McLeod W for the TEDDY Study Group, Annual meeting of the American Diabetes Association, Chicago, IL, USA: June 2007.
9. Characterization of CD4⁺CD25⁺ regulatory T cells during the first year of life based on the expression of the transcription factor forkhead box P3 (FOXP3), Åkesson C, Nyholm C, Blom E, Arvastsson J, Cilio CM for the TEDDY Study Group, 13th International Congress of Immunology, Rio de Janeiro, Brazil: August 2007.
10. The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Rewers M for the TEDDY Study Group, Annual meeting of the European Association for the Study of Diabetes, Amsterdam, Netherlands: September 2007.
11. TEDDY Study Group (MJ Haller member, Clinical Implementation Committee Chair). The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Immunology of Diabetes V: Annals of the New York Academy of Sciences, 1150:1-13, 2008. PMID 19120261
12. Enrollment, retention, and compliance challenges in an intensive long-term prospective study: The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Gesualdo P, Ide L, Barriga K, Waugh K, Rewers M, Baxter J for the TEDDY Study Group, 26th Epidemiologic Research Exchange, Denver, CO, USA: April 2008.
13. Infant feeding patterns during the first year of life in the offspring of mothers with and without type 1 diabetes: results from the TEDDY (The Environmental Determinants of Diabetes in the Young) Study, Hummel S, Schoen S, Norris JM, Virtanen SM, McLeod W, Andren Aronsson C and Gesualdo P for the TEDDY Study Group, German Diabetes Association, Munich, Germany: May 2008.
14. Psychosocial Stress: Negative Life Events in TEDDY (The Environmental Determinants of Diabetes in the Young), Roth R, Johnson SB, Lernmark B, Baxter J, Simell T, McLeod W and the TEDDY Study Group, German Diabetes Association, Munich, Germany: May 2008.
15. Food composition database harmonization for between country comparisons of dietary data in the TEDDY Study (The Environmental Determinants of Diabetes in the Young), Uusitalo U, Aronsson CA, Ovaskainen ML, Kronberg-Kippila C, Mattisson I, Schakel S, Sichert-Hellert W, Schoen S, Stevens M, Norris JM and Virtanen SM for the TEDDY Study Group, National Nutrient Database Conference, Ottawa, Ontario, Canada: May 2008.
16. Psychosocial Stress: Negative Life Events in TEDDY (The Environmental Determinants of Diabetes in the Young), Roth R, Johnson SB, Lernmark B, Baxter J, Simell T, McLeod W, the TEDDY Study Group, XXIX International Congress of Psychology, Berlin, Germany: July 2008.

17. Infant feeding patterns during the first year of life in the offspring of mothers with and without type 1 diabetes: results from the TEDDY (The Environmental Determinants of Diabetes in the Young) Study, Hummel S, Schoen S, Norris JM, Virtanen SM, McLeod W, Andren Aronsson, Gesualdo P for the TEDDY Study Group, Annual meeting of the European Association for the Study of Diabetes, Rome, Italy: September 2008.
18. Maternal Feeding Practices Among Infants with Genetic Predisposition to Type 1 Diabetes: Results from the TEDDY (The Environmental Determinants of Diabetes in the Young) Study, Andren Aronsson C, Hay K, Kyttälä P, Schoen S, Shankar M, Silvis K, Yang J, Virtanen SM, and Norris JM for the TEDDY Study Group, American Dietetic Association Food & Nutrition Conference& Expo, Chicago, IL, USA: October 2008.
19. The Environmental Determinants of Diabetes in the Young (TEDDY): Denver, Colorado, Blair A, Ide L, Nallamshetty L, Alejandrino M, Bogale M, Baxter J, Waugh K, Bugawan TL, Rewers M, Erlich HA and the TEDDY Study Group, 34th Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Toronto Canada: October 2008.
20. Is the Increase in Type 1 Diabetes Incidence due to Faster Progression from Antibody Positivity to Disease?, Ziegler A, Pflüger M, Knopff A, Winkler C for the TEDDY Study Group, Annual meeting of the German Diabetes Association, Leipzig, Germany: May 2009; 10th meeting of the Immunology of Diabetes Society, Malmö, Sweden: May 2009.
21. Birth length differs by type 1 diabetes high-risk HLA genotypes in the TEDDY study, Sterner Y, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler A, Schatz D, Hagopian W, Rewers M, She J-X, Krischer J, Akolkar B, Lernmark Å for the TEDDY Study Group, 10th meeting of the Immunology of Diabetes Society, Malmö, Sweden: May 2009.
22. Sample flow in TEDDY Sweden laboratories, Torn C, Carlsson U-M, Gerardsson J, Gustavsson U, Markan M, Rahmati K, Sjöberg B, Wallin A, Wigheden I for the TEDDY Study Group, 10th meeting of the Immunology of Diabetes Society, Malmö, Sweden: May 2009.
23. Blood sampling in the Sweden TEDDY study, Hansson G, Wallin A, Sjöberg B, Andersson E, Bremer J, Melin J, Andersson-Turpeinen M, Ask M, Hansen M, Sedig-Jarvirova M, Hyberg S, Carlsson U-M, Wimar Å for the TEDDY Study Group, 10th meeting of the Immunology of Diabetes Society, Malmö, Sweden: May 2009.
24. Major Population Differences in The Risk of Early Islet Autoimmunity in Children With Identical HLA-DR-DQ Genotypes, Rewers M for the TEDDY Study Group, Annual meeting of the American Diabetes Association, New Orleans, LA, USA: June 2009.
25. Food composition database harmonization for between-country comparisons of dietary data in the TEDDY Study, U Uusitalo, C Kronberg-Kippilä, CA Aronsson, ML Ovaskainen, I Mattisson, S Schakel, W Sichert-Hellert, S Schoen, M Stevens, H

Reinivuo, JM Norris and SM Virtanen for the TEDDY Study Group, European Association for the Study of Diabetes, Vienna, Austria: October 2009.

26. Hye-Seung Lee, Carina Törn, Kendra Vehik, Jeffrey P. Krischer, Kristian F. Lynch, Helena Elding Larsson, Michael Haller, William A. Hagopian, Marian J. Rewers, Jin-Xiong She, Olli G. Simell, Jorma Toppari, Anette-G. Ziegler, Beena Akolkar, Ezio Bonifacio, Åke Lernmark and the TEDDY Study Group. Factors affecting the risk for the first appearance of an islet autoantibody in The Environmental Determinants of Diabetes in the Young (TEDDY) study. 51st EASD Annual Meeting, Stockholm, Sweden 9/14/15-9/18/15. Oral

Publications:

1. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: Study Design, The TEDDY Study Group, *Pediatric Diabetes*. 2007 Oct;8(5): 286–98. PMID: 17850472
2. A High Throughput Population Screening System for the Estimation of Genetic Risk for Type 1 Diabetes - An Application for the TEDDY (The Environmental Determinants of Diabetes in the Young) Study, Kiviniemi M, Hermann R, Nurmi J, Ziegler A, Knip M, Simell O, Veijola R, Lövgren T, Ilonen J and the TEDDY Study Group, *Diabetes Technology and Therapeutics*. 2007; 9(5): 460-472. PMID: 17931054
3. Trans-Atlantic Data Harmonization in the Classification of Medicines and Dietary Supplements: A Challenge for Epidemiologic Study and Clinical Research. Moyers S, Richesson RL, Krischer J. *International Journal of Medical Informatics*. 2008; 77: 58-67. PMID:17289429 PMID: PMC2259273
4. The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Rewers M and the TEDDY Study Group, *Annals of the New York Academy of Science*. Volume: Immunology of Diabetes V. 2008; 1150:1-13. PMID: 19120261 PMID: PMC2886800
5. Achieving Standardized Medication Data in Clinical Research Studies: Two Approaches and Applications for Implementing RxNorm, Richesson RL, Smith S, Malloy J, Krischer J. *J Med Syst*. 2010 Aug;34(4):651-7. doi: 10.1007/s10916-009-9278-5. Epub 2009 Apr 3. PMID: 20703919 PMID: PMC2977947
6. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: Predictors of Early Study Withdrawal Among Participants with No Family History of Type 1 Diabetes, Johnson SB, Lee HS, Baxter J, Lernmark B, Roth R, Simell T for the TEDDY Study Group. *Pediatr Diabetes*. 2011 May;12(3 Pt 1):165-71. doi: 10.1111/j.1399-5448.2010.00686.x. Epub 2010 Oct 28. PMID: 21029290 PMID: PMC3032020
7. Country-specific birth weight and length in type 1 diabetes high-risk HLA genotypes in combination with prenatal characteristics, Sterner Y, Törn C, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler A, Schatz D, Hagopian W, Rewers

- M, She J-X, Krischer J, Akolkar B and Lernmark Å for the TEDDY Study Group, *J Perinatol*. 2011 Dec;31(12):764-9. doi: 10.1038/jp.2011.26. Epub 2011 Apr 28. PMID: 21527903 PMID: PMC3226663
8. The Environmental Determinants of Diabetes in the Young (TEDDY): Genetic Criteria and International Diabetes Risk Screening of 421,000 infants, Hagopian W, Erlich H, Lernmark Å, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt R, Blair A, Ilonen J, Krischer J and She JX for the TEDDY Study Group, *Pediatric Diabetes* 2011 Dec;12(8):733-43. doi: 10.1111/j.1399-5448.2011.00774.x. Epub 2011 May 12. PMID: 21564455 PMID: PMC3315186
 9. Food Composition Database Harmonization for Between Country Comparisons of Nutrient Data in the TEDDY Study, Uusitalo U, Kronberg-Kippilä C, Aronsson CA, Schakel S, Schoen S, Mattisson I, Reinivuo H, Silvis K, Sichert-Hellert W, Stevens M, Norris JM, Virtanen SM and the TEDDY Study Group, *J Food Compost Anal*. 2011 Jun;24(4-5):494-505. PMID:22058606 PMID: PMC3205351
 10. Enrollment Experiences in a Pediatric Longitudinal Observational Study: The Environmental Determinants of Diabetes in the Young (TEDDY) Study, Lernmark B, Johnson SB, Vehik K, Smith L, Ballard L, Baxter J, McLeod W, Roth R, Simell T on behalf of the TEDDY Study Group. *Contemp Clin Trials*. 2011 Jul;32(4):517-23. doi: 10.1016/j.cct.2011.03.009. Epub 2011 Mar 17. PMID:21419878 PMID: PMC3118988
 11. Detection of laktobacilli in monthly mail-in stool samples from 3-18 months old infants at genetic risk for type 1 diabetes. Salami F, Abels M, Vaziri-Sani F, Aronsson C, Vehik K, Delli A, Hagopian W, Rewers M, Ziegler A, Simell O, Akolkar B, Krischer J, She J, Lernmark A; the TEDDY study group. *Int J Probiotics Prebiotics*. 2012 Aug;7(3-4):135-144. PMID: 25045339 PMID: PMC4101081
 12. Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up, Helena Elding Larsson, Kendra Vehik, Ronny Bell, Dana Dabelea, Lawrence Dolan, Catherine Pihoker, Mikael Knip, Riitta Veijola, Bengt Lindblad, Ulf Samuelsson, Reinhard Holl, Michael Haller on behalf of the TEDDY Study Group, SEARCH Study Group, Swediabkids Study Group, DPV Study Group and Finnish Diabetes Registry Study Group, *Diabetes Care*. 2011 Nov;34(11):2347-52. doi: 10.2337/dc11-1026. Epub 2011 Oct 4. PMID: 21972409 PMID: PMC3198296
 13. Differences in recruitment and early retention among ethnic minority participants in a large pediatric cohort: The TEDDY Study, Baxter J, Vehik K, Johnson SB, Lernmark B, Roth R, Simell T and the TEDDY Study Group, *Contemp Clin Trials*. 2012 Jul;33(4):633-40. doi: 10.1016/j.cct.2012.03.009. Epub 2012 Mar 29 PMID: 22484339 PMID: PMC3686560
 14. Reasons for staying as a participant in The Environmental Determinants of Diabetes in the Young (TEDDY) longitudinal study. Barbro Lernmark, Kristian Lynch, Lori Ballard,

- Judith Baxter, Roswith Roth, Tuula Simell and Suzanne Johnson and the TEDDY Study Group, *J Clin Trials*. 2012;2(2). pii: 1000114. PMID:23894727 PMCID: PMC3723141
15. Maternal life stress, post-partum depression and anxiety about child's diabetes risk during the first 6 months in The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Roswith Roth, Kristian Lynch, Lori Ballard, Barbro Lernmark, Judith Baxter, Tuula Simell, Laura Smith, Suzanne B Johnson and the TEDDY Study Group, *Pediatr Diabetes*. 2014 Aug 1. doi: 10.1111/pedi.12168. [Epub ahead of print]. PMID:25082392 PMCID: PMC4312746
 16. Infant feeding patterns in families with a diabetes history – observations from The Environmental Determinants of Diabetes in the Young (TEDDY) birth cohort study. Sandra Hummel, Kendra Vehik, Ulla Uusitalo, Wendy McLeod, Carin Aronsson, Nicole Frank, Patricia Gesualdo, Jimin Yang, Jill Norris, Suvi Virtanen and the TEDDY Study Group, *Public Health Nutr*. 2014 Dec;17(12):2853-62.doi:10.1017/S1368980013003054. Epub 2013 Nov 26. PMID:24477208 PMCID: PMC4162845
 17. Use of Dietary Supplements in relation to sociodemographic determinants in pregnant women in the TEDDY-study. Aronsson CA, Vehik K, Uusitalo U, Hay K, Joslowski G, Riikonen A, Ballard L, Virtanen SM, Norris JM, and the TEDDY Study Group, *Public Health Nutr*. 2013 Aug;16(8):1390-402. doi: 10.1017/S1368980013000293. Epub 2013 Mar 4. PMID: 23452986 PMCID: PMC4112516
 18. High Risk for Early Study Withdrawal: Potential Impact of a Tailored Intervention on Study Retention in the First Year of TEDDY – Johnson SB, Lynch KF, Lee HS, Baxter J, Lernmark B, Roth R, Simell T, Smith L, and the TEDDY Study Group. *J Clin Epidemiol*. 2014 Jun;67(6):609-11. doi: 10.1016/j.jclinepi.2014.01.004. Epub 2014 Apr 13. PMID: 24725640 PMCID: PMC4159066
 19. Next-generation sequencing for viruses in children with rapid-onset type 1 diabetes. Lee HS, Briese T, Winkler C, Rewers M, Bonifacio E, Hyoty H, Pflueger M, Simell O, She JX, Hagopian W, Lernmark A, Akolkar B, Krischer JP, Ziegler AG; TEDDY study group. *Diabetologia*. 2013 Aug;56(8):1705-11. doi: 10.1007/s00125-013-2924-y. Epub 2013 May 9. PMID: 23657799 PMCID: PMC4019381
 20. Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Vehik K, Fiske SW, Logan CA, Agardh D, Cilio CM, Hagopian W, Simell O, Roivainen M, She JX, Briese T, Oikarinen S, Hyoty H, Ziegler AG, Rewers M, Lernmark A, Akolkar B, Krischer JP, Burkhardt BR; TEDDY Study Group. *Diabetes Metab Res Rev*. 2013 Oct;29(7):557-67. doi: 10.1002/dmrr.2427. PMID: 23674484 PMCID: PMC3992860

21. Age at first introduction to complementary foods is associated with sociodemographic factors in children with increased genetic risk of developing type 1 diabetes. Andrén Aronsson C, Uusitalo U, Vehik K, Yang J, Silvis K, Hummel S, Virtanen SM, Norris JM; TEDDY Study Group. *Matern Child Nutr.* 2013 Sep 13. doi: 10.1111/mcn.12084. [Epub ahead of print]. PMID: 24034553 PMCID: PMC4122645
22. Factors associated with maternal-reported actions to prevent type 1 diabetes in the first year of the TEDDY study. Smith LB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, Johnson SB; TEDDY Study Group. *Diabetes Care.* 2014 Feb;37(2):325-31. doi: 10.2337/dc13-0449. Epub 2013 Sep 16. PMID: 24041684 PMCID: PMC3898752
23. Biomarker discovery study design for type 1 diabetes in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Lee HS, Burkhardt BR, McLeod W, Smith S, Eberhard C, Lynch K, Hadley D, Rewers M, Simell O, She JX, Hagopian B, Lernmark A, Akolkar B, Ziegler AG, Krischer JP; TEDDY study group. *Diabetes Metab Res Rev.* 2014 Jul;30(5):424-34. doi: 10.1002/dmrr.2510 PMID: 24339168 PMCID: PMC4058423
24. Prevalence of obesity was related to HLA-DQ in 2-4-year-old children at genetic risk for type 1 diabetes. Yang J, Lernmark Å, Uusitalo UM, Lynch KF, Veijola R, Winkler C, Larsson HE, Rewers M, She JX, Ziegler AG, Simell OG, Hagopian WA, Akolkar B, Krischer JP, Vehik K; TEDDY Study Group. *Int J Obes (Lond).* 2014 Dec;38(12):1491-6. doi: 10.1038/ijo.2014.55. Epub 2014 Apr 3. PMID: 24694666 PMCID: PMC4185013
25. Risk of pediatric celiac disease according to HLA haplotype and country. Liu E, Lee HS, Aronsson CA, Hagopian WA, Koletzko S, Rewers MJ, Eisenbarth GS, Bingley PJ, Bonifacio E, Simell V, Agardh D; TEDDY Study Group. *N Engl J Med.* 2014 Jul 3;371(1):42-9. doi: 10.1056/NEJMoa1313977. PMID: 24988556 PMCID: PMC4163840
26. Two applications of permutation tests in biostatistics. León-Novelo L, Kempainen KM, Ardisson A, Davis-Richardson A, Fagen J, Gano K, Triplett EW; TEDDY STUDY GROUP. *Bol Soc Mat Mex.* 2013 Oct 1;19(2):255-266. *Bol Soc Mat Mex.* 2013 Oct 1;19(2):255-266. PMID: 25221355 PMCID: PMC4159102
27. Role of Type 1 diabetes associated SNPs on risk of autoantibody positivity in the TEDDY Study. Törn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler A, Schatz D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkänen J, Ilonen J, Rich SS, Steck AK, Krischer J; the TEDDY Study Group. *Diabetes.* 2014 Nov 24. pii: DB_141497. [Epub ahead of print] PMID: 25422107 PMCID: PMC4407865
28. Early childhood gut microbiomes show strong geographic differences among subjects at high risk for type 1 diabetes. Kempainen KM, Ardisson AN, Davis-Richardson AG, Fagen JR, Gano KA, León-Novelo LG, Vehik K, Casella G, Simell O, Ziegler AG,

- Rewers MJ, Lernmark Å, Hagopian W, She JX, Krischer JP, Akolkar B, Schatz DA, Atkinson MA, Triplett EW; TEDDY Study Group. *Diabetes Care*. 2015 Feb;38(2):329-32. doi: 10.2337/dc14-0850. Epub 2014 Dec 17. PMID: 25519450 PMID: PMC4302256
29. Age at gluten introduction and risk of celiac disease. Aronsson CA, Lee HS, Liu E, Uusitalo U, Hummel S, Yang J, Hummel M, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Krischer J, Virtanen SM, Norris JM, Agardh D; TEDDY study group. *Pediatrics*. 2015 Feb;135(2):239-45. doi: 10.1542/peds.2014-1787. Epub 2015 Jan 19. PMID: 25601977 PMID: PMC4306795
 30. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Krischer JP¹, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group. *Diabetologia*. 2015 May;58(5):980-7. doi: 10.1007/s00125-015-3514-y. Epub 2015 Feb 10. PMID: 25660258 PMID: PMC4393776
 31. Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, She J, Simell O, Akolkar B, Krischer J, Schatz D⁰, Rewers MJ¹; and the TEDDY Study Group. *Diabetes Care*. 2015 Feb 9. pii: dc142426. [Epub ahead of print] PMID: 25665818 PMID: PMC4407751
 32. Clinical features of celiac disease: a prospective birth cohort. Agardh D, Lee HS, Kurppa K, Simell V, Aronsson CA, Jörneus O, Hummel M, Liu E, Koletzko S; TEDDY Study Group. *Pediatrics*. 2015 Apr;135(4):627-34. doi: 10.1542/peds.2014-3675. Epub 2015 Mar 2. PMID: 25733751 PMID: PMC4379464
 33. A method for reporting and classifying acute infectious diseases in a prospective study of young children. Lönnrot M, Lynch K, Larsson HE, Lernmark Å, Rewers M, Hagopian W, She JX, Simell O, Ziegler AG, Akolkar B, Krischer J, Hyöty H; TEDDY study group. *BMC Pediatr*. 2015 Mar 20;15:24. doi: 10.1186/s12887-015-0333-8. PMID: 25884839 PMID: PMC4377063
 34. Factors affecting the risk for the first appearance of an islet autoantibody in The Environmental Determinants of Diabetes in the Young (TEDDY) study. Hye-Seung Lee, Carina Törn, Kendra Vehik, Jeffrey P. Krischer, Kristian F. Lynch, Helena Elding Larsson, Michael Haller, William A. Hagopian, Marian J. Rewers, Jin-Xiong She, Olli G. Simell, Jorma Toppari, Anette-G. Ziegler, Beena Akolkar, Ezio Bonifacio, Åke Lernmark and the TEDDY Study Group.

35. Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. Krischer JP, Liu X, Vehik K, Akolkar B, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG, Lernmark Å; TEDDY Study Group. *Diabetes Care*. 2019 Apr 9. pii: dc182282. doi: 10.2337/dc18-2282. [Epub ahead of print] PMID:30967432

TrialNet/DPT-1 Study Group

Published Manuscripts

1. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial- Type 1. *Diabetes Care* 2007; 30:38-42. PMID : 17192330
2. Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study. *Diabetologia* 2007; 50:1603-1606. PMID:17583798
3. Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-Type 1 Study Group. The Role of Insulin Resistance in Predicting the Progression to Type 1 Diabetes. *Diabetes Care* 2007; 30:2314–2320. PMID: 17536068
4. Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes Prevention Trial for Type 1 Diabetes. *Diabetes Care*, 2007; 30: 2193–2198. PMID:17563348
5. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS, and the Diabetes Prevention Trial-1 Study Group. A Risk Score for Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention Trial-Type 1. *Diabetes Care* 2008; 31: 528-533. PMID 18000175
6. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Glucose and C-peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2008; 31: 2188-2192. PMID 18650369 PMCID: PMC2571043
7. Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study Group. Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the DPT1 trial. *Diabetes* 2008; 57: 2348-2359. PMID 18556337 PMCID: PMC2518486

8. Sherr J, Sosenko J, Skyler JS, Herold K. Prevention of Type 1 diabetes. The time has come. *Nature Clinical Practice Endocrinology & Metabolism* 2008; 4:334-343. PMID 18446141
9. Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group. Participant and parent experiences in the oral insulin study of the Diabetes Prevention Trial for Type 1 Diabetes. *Pediatric Diabetes* 2009; 10:177-183. PMID:18823410
PMCID: PMC4206940
10. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. Incident Dysglycemia and the Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1. *Diabetes Care* 2009; 32: 1603-1607 Jun 1. PMID 19487644 PMCID: PMC2732147
11. Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. *Diabetes Care* 2009; 32:769-773. PMID 19407074
PMCID: PMC2671125
12. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G, and the DPT- Study Group. Pancreatic Islet Cell Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes Care* 2009;32:2269-2274 PMID 19741189 PMCID: PMC2782989
13. Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth GS, Skyler JS, and the DPT-1 Study Group. Trends of Earlier and Later Responses of C-Peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. *Diabetes Care* 2010;33:620-625. PMID 20032282 PMCID: PMC2827520
14. Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS< for the DPT-1 Study Group. Progression to Diabetes in Relatives of Patients with Type 1 Diabetes: Mechanisms and Mode of Onset. *Diabetes* 2010;59:679-685. PMID 20028949 PMCID: PMC2828663
15. Lachin JM, Younes N. A composite design for transition from a preliminary to a full-scale study. *Statistics in Medicine* 2007; 26:5014–5032. PMID: 17577245
16. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and the Type 1 Diabetes TrialNet Study Group. Type 1 Diabetes TrialNet – An International Collaborative Clinical Trials Network. *Annals of the New York Academy of Sciences* 2008; 1150: 14-24. PMID 19120262 PMCID: PMC2918900 NIHMS 225039
17. Skyler JS; Type 1 Diabetes TrialNet Study Group. Update on Worldwide Efforts to Prevent Type 1 Diabetes. *Annals of the New York Academy of Sciences* 2008; 1150: 190-196. PMID 19120293 PMCID: PMC2928677 NIHMS22502

18. Greenbaum CJ, Mandrup-Poulsen T, FriedenberG-McGee P, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group. Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β -Cell Function in Therapeutic Trials in Type 1 Diabetes. *Diabetes Care* 2008; 31: 1966-1971. PMID 18628574
PMC2251636
19. Mahon J, Sosenko JM, Rafkin-Mervis LE, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group. The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatric Diabetes* 2009; 10:97-104. PMID 18823409
20. Chase HP, Leschek E, Rafkin-Mervis L, Krause-Steinrauf J, Chritton S, Asare SM, Adams S, Skyler JS, Clare-Salzler M, and the Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes; A Pilot Trial. *ICAN: Infant, Child, & Adolescent Nutrition* 2009; 1:98-107.
21. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz D, Wherrett D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function. *New England Journal of Medicine* 2009; 361:2143-2152. PMID 19940299
22. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS, and the TrialNet MMF/DZB Study Group. Failure to Preserve beta-cell function with Mycophenolate Mofetil and Daclizumab Combined Therapy in patients with new onset Type 1 Diabetes. *Diabetes Care*, 2010;33:826-832. PMID 20067954 PMCID:PMC2845036
23. Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb PA, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, and The Type 1 Diabetes TrialNet Research Group. Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays in Subjects with Early Type 1 Diabetes. *Diabetes* 2009; 58: 2588-2595. PMID 19675135 PMCID: PMC2768166
24. Yu L, Johnson K, Scrimgeour L, Miao D, Hutton J, Mahon J, Eisenbarth GS, and Type 1 Diabetes TrialNet Study Group. ZnT8 Autoantibody Testing Enhances Detection of Multiple Autoantibody-Positive Relatives. Submitted for Publication.
25. Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. A Comparison of the Baseline Metabolic Profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study Participants. Submitted for Publication.

26. Bingley PJ, Matthews CL. Type 1 Diabetes TrialNet: Working Together to Prevent, Delay or Slow the Progression of Type 1 Diabetes. *Pract Diab Int* 2010;27:98-99i.
27. Sosenko J, Skyler J, Krischer J, Greenbaum C, Mahon J, Rafkin-Mervis L, Cuthbertson D, Cowie C, Herold K, Eisenbarh G, Palmer J, the Diabetes Prevention Trial-1 Study Group. Glucose Excursions between States of Glycemia with Progression to Type 1 Diabetes in the Diabetes Prevention Trial Type 1 (DPT-1). *Diabetes* 2010;59:2386-2389. PMID 20682683 PMID: PMC3279562
28. Xu P, Wu y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer J, Skyler J, Sosenko J, and the Diabetes Prevention Trial-1 Study Group. Prognostic Performance of Metabolic Indexes in Predicting Onset of Type 1 Diabetes. *Diabetes Care* 2010;33:2508-2513. PMID 20807869 PMID:PMC2992179
29. Sosenko JM, Mahon J, Rafin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. A Comparison of the Baseline Metabolic Profiles Between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study Participants. *Pediatric Diabetes* 2011;12:85-90. PMID 20522170, NIHMS213978, PMID: PMC2955175
30. Greenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B. Parenteral Insulin Suppresses T Cell Proliferation to Islet Antigens. *Pediatric Diabetes* 2011;12:150-155. PMID 20522167. NIHMS213975, PMID: PMC2957543
31. Greenbaum CJ, Buckingham B, Chase HP, Krischer J. Metabolic Tests to Determine Risk for Type 1 Diabetes in Clinical Trials. *Diabetes Metab Res Rev* 2011;27:584-589. PMID 21488143, NIHMS287843, PMID: PMC3162108
32. Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, on behalf of the DPT-1 & TrialNet Study Groups. Long Term Outcome of Individuals Treated with Oral Insulin: Diabetes Prevention Trial-Type 1 (DPT-1) Oral Insulin Trial. *Diabetes Care* 2011;34:1585-1590. PMID: 21610124, PMID: PMC3120180
33. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin L, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial – Type 1 Study Groups. The Validation of the Diabetes Prevention Trial-Type 1 Risk Score and the Detection of Pre-Diabetes in the TrialNet Natural history Study. *Diabetes Care* 2011;34:1785-1787. PMID:21680724, PMID:PMC3142063.
34. Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: A Randomized Double-Masked Controlled Trial. *Lancet* 2011;378:412-419. PMID 21719096 PMID: PMC3462593

35. Wherrett D, Bundy B, Becker DJ, MiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodrigues H, Schatz D, Wilson DM, Krischer JP, Skyler JS, the TrialNet GAD Study Group. Antigen-Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with Recent-Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. *Lancet* 2011;378:319-327. PMID 21714999 PMCID: PMC3580128
36. Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z, Lachin J, Dosch HM, for the Type 1 Diabetes Trial Net Study Group. Increased T Cellular Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. *J Immunology* 2011;187:1998-2005. PMID 21775681, PMCID: PMC3150302, NIHMS303803
37. Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab Selectively Suppresses Specific Islet Antibodies. *Diabetes* 2011;60:2560-2565. PMCID:21831969, PMCID: PMC3178300
38. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups. A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. Brief Report *Diabetes Care* 2011;34:2435-2437. PMID 21911777, PMCID: PMC3198298
39. Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer UP, Winter William E, Skyler JS, Krischer JP and the Type 1 Diabetes TrialNet Study Group. Comparison of Two Insulin Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies. *Clin Chim Acta* 2011;412:2128-2131. PMID 21843518, PMCID: PMC3150302, NIHMS303803
40. Pescovitz M, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, the Type 1 Diabetes TrialNet Study Group. Effect of Rituximab on Human in Vivo Antibody Immune Responses. *J Allergy Clin Immunol* 2011 Dec;128(6):1295-1302.e5. doi: 10.1016/j.jaci.2011.08.008. Epub 2011 Sep 9. PMID 21908031 PMCID: PMC3659395
41. Lachin J, Friedenber-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb P, Skyler J, for the Type 1 Diabetes TrialNet Study Group. Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. *PLoS One*. 2011;6(11):e26471. doi: 10.1371/journal.pone.0026471. Epub 2011 Nov 10. PMID:22102862 PMCID: PMC3213096
42. Yu L, Boulware DC, Beam CA, John C. Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL for the Type 1 Diabetes TrialNet Study Group. Zinc Transporter-8 Autoantibodies Improve Prediction of

- Type 1 Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. *Diabetes Care* 2012;35:1213-1218. PMID 22446173 PMCID: PMC3357246
43. * Sosenko JM, Skyler JS, Herold KC, Palmer JP. The Metabolic Progression to Type 1 Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention Trial-Type 1. *Diabetes* 2012;61:1331-1337. PMID 22618768 PMCID: PMC3357303
 44. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. Fall in C-peptide Over First Two Years from Diagnosis: Evidence of At Least Two Distinct Phases from Composite TrialNet Data. *Diabetes* 2012;61:2066-2073. PMID 22688329 PMCID: PMC3402330
 - 45.* Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, The TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Application of the Diabetes Prevention Trial Risk Score (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. *Diabetes Care* 2012;35:1552-1555. PMID 2254709 PMCID: PMC3379597
 46. Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups. Performance of HbA1c as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. *Diabetes Care* 2012;35:1821-1825. PMID 22699293 PMCID: PMC3425003
 47. * Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP and the DPT-1 Study Group.. Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in a High Risk Population - Receiver Operating Characteristic Analysis. *Diabetes Care* 2012;35:1975-1980. PMID 22787174 PMCID: PMC3447832
 48. Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; for the Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes Augments Tregs yet Transiently Impairs β -Cell Function. *Diabetes* 2012; 61:2340-2348. PMID 22721971 PMCID: PMC3425404
 49. * Sajjadi SJ, Qian X, Zeng B. Network-Based Methods to Identify Highly Discriminating Subsets of Biomarkers. 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), "Data Mining and Modeling Methods in Next-Generation Sequencing and Cancer Systems Biology". Washington DC, December 2-4, 2012, *IEEE Xplore*, p.139-142.
 50. * Adl AA, Qian X, Xu P, Vehik K, Krischer JP. Feature Ranking Based on Synergy Networks to Identify Prognostic Markers in DPT-1. 2012 IEEE International Workshop on Genomic Signal Processing and Statistics (GENSIPS), "Data Mining and Modeling

Methods in Next-Generation Sequencing and Cancer Systems Biology". Washington DC, December 2-4, 2012, *IEEE Xplore*, p. 66-69.

51. Alkanani AK, Rewers M, Waugh K, Barriga K, Gottlieb PA, Zipris D. Dysregulated Toll-like Receptor-induced Interleukin-1 β and Interleukin-6 Responses in Subjects at Risk for the Development of Type 1 Diabetes. *Diabetes* 2012;61:2525-2533. (TrialNet Ancillary Study). PMID 22751696 PMID: PMC3447890
52. Han DM, Cai X, Wen J, Matheson D, Skyler JS, Kenyon NS, Chen Z: Innate and Adaptive Immune Gene Expression Profiles as Biomarkers in Human Type 1 Diabetes. *Clin Exp Immunol* 2012;170:131-138. PMID 23039883 PMID: PMC3482359
53. Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group. Epstein Barr & Other Herpesvirus Infections in Patients with Early Onset Type 1 Diabetics Treated with Daclizumab & Mycophenolic Mofetil. *Clinical Infectious Diseases* 2013; 56:248-254. PMID 23042974 PMID: PMC3526252.
- 54.* Adl AA, Qian X, Xu P, Vehik K, Krischer JP. Feature Ranking Based on Synergy Networks to Identify Prognostic Markers in DPT-1. *EURASIP J Bioinform Syst Biol* 2013;Sept 19, 2013:12. PMID 24050757 PMID: PMC3849336.
55. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Sanda S, Raskin P, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Pickersgill L, de Koning E, Ziegler A-G, Boehm B, Badenhop K, Schloot N, Bak JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T. Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two Multicenter, Randomized Double-Masked, Placebo-Controlled Trials. *Lancet* 2013;381:1905-1915. PMID 23562090 PMID: PMC3827771.
56. Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet Anti CD-20 Study Group. Reactivation of Latent Viruses in Individuals Receiving Rituximab for New Onset Type 1 Diabetes. *J Clin Virol* 2013;57:115-119. PMID 23422292 PMID: PMC3640764.
57. Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Groups, Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Cantwell M. The Effects of Inpatient Hybrid Closed-Loop Therapy Initiated within 1 Week of Type 1 Diabetes Diagnosis. *Diabetes Technol Ther* 2013;15:401-408. PMID 23570538 PMID: PMC3643224.
58. Elding Larsson H, Jönsson I, Åke Lernmark Å, Ivarsson S, Radtke JR, Hampe CS and the Diabetes Prediction in Skåne (DiPiS) and Type 1 Diabetes TrialNet studies. Decline in Titers of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes Development of GAD65Ab and Type 1 Diabetes. *Plos One* 2013;8(6):e65173. PMID 23785410 PMID: PMC3681789.

- 59.* Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups. The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1 Diabetes Patients. *Diabetes Care* 2013;36:2615-2620. PMID 23818528 PMCID: PMC 3747899
60. Weinberg A, Boulware D, Dighero B, Orban T, for the Type 1 Diabetes Abatacept Study Team. Effect of Abatacept on Immunogenicity of Vaccines in Individuals with Type 1 Diabetes. *Vaccine* 2013;31:4791-4794. PMID 23962535 PMCID: PMC3803163
61. Krischer JP, the Type 1 Diabetes TrialNet Study Group. The Use of Intermediate Endpoints in the Design of Type 1 Diabetes Prevention Trials. *Diabetologia* 2013;56:1919-1924. PMID 23744306 PMCID: PMC3743228
- 62.* Ismail H, Krischer J, Chase HP, Cuthbertson D, Palmer J. First Test Effect in Intravenous Glucose Tolerance Testing. *Pediatric Diabetes* 2013, Aug 15 Epub ahead of print. PMID 23944770 PMCID: PMC3838455 (available 3/1/16).
- 63.* Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, and the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial-Type 1 Study Groups. Acceleration of the Loss of the First-Phase Insulin Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants. *Pediatr Diabetes*. 2015 Mar;16(2):129-37. doi: 10.1111/pedi.12064. Epub 2013 Aug 15. PMID 23863814 PMCID: PMC3837047
64. Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV;Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. Effectiveness of Early Intensive Therapy on Beta-Cell Preservation in Type 1 Diabetes. *Diabetes Care*. 2013 Dec;36(12):4030-5. doi: 10.2337/dc13-1074. Epub 2013 Oct 15. PMID 24130350 PMCID: PMC3836135
65. McCarlie VW, Hartsfield Jr JK, Blum JS, Gonzalez-Cabezar C, Chin JR, Eckert GJ, Morford L, Pescovitz M, Rodriguez H, Fontaina M, Gregory RL. Total IgA and IgA Reactivity to Antigen I/II Epitopes in HLA-DRB1*04 Positive Subjects. *Open J Immunol*. 2013 Sep 1;3(3). doi: 10.4236/oji.2013.33012 PMID: 24386612 PMCID: PMC3875298 (Ancillary Study).
66. Valle A, Giamporcaro GM, Scavini M, Stabilini A, Grogan P, Bianconi E, Sebastiani G, Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M. Reduced Circulating Neutrophils Precedes and Accompanies Type 1 Diabetes. *Diabetes* 2013;62:2072-2077. PMID 23349491 PMCID: PMC3661622 (Ancillary Study).

67. Pescovitz M, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JP, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. *Diabetes Care* 2014;37:453-459. PMID 24026563 PMCID: PMC3898764
68. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; the Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. *Diabetes Care* 2014;37:979-984. PMID 24550217 PMCID: PMC3964487
69. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, the Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-up One Year After Cessation of Treatment. *Diabetes Care* 2014;37:1069-1075. PMID 24296850, PMCID: PMC3964491
70. * Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, and the DPT-1 Study Group. Distribution of C-Peptide and its Determinants in North American Children at Risk for Type 1 Diabetes. *Diabetes Care* 2014;37:1959-1965. PMID 24760262, PMCID: PMC4067394
71. Max Andersen ML, Nielsen LB, Svensson J, Porksen S, Hougaard P, Beam C, Greenbaum C, Becker D, Petersen JS, Hansen L, Mortensen HB. Disease Progression Among 446 Children with Newly Diagnosed Type 1 Diabetes Located in Scandinavia, Europe and North America during the Last 27 Years. *Pediatric Diabetes* 2014;15:345-354. PMID 24731251, PMCID: PMC- in process.
72. Beam CA, Gitelman SE, Palmer J and the Type 1 Diabetes TrialNet Study Group. Recommendations for the Definition of Clinical Responder in Insulin Preservation Studies. *Diabetes* 2014;63:3120-3127. PMID 24722251, PMCID: PMC4141373
73. Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L, Peakman M, and the Type 1 Diabetes TrialNet Abatacept Study Group. Reduction in CD4 Central Memory T-cell subset in Co-Stimulation Modulator Abatacept-Treated Patients with Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide Decline. *Diabetes* 2014;63:3449-3457. PMID 24834977, PMCID: PMC4171657
74. Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J, Type 1 Diabetes TrialNet. Screening and Monitoring of Infectious Complications when Immunosuppression Agents are Studied in the Treatment of Autoimmune Disorders. *J Ped Infect Dis Soc* 2014; June 26 Epub ahead of print, accepted 5/14/14.

75. Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J, Skyler JS, Clare-Salzler M, Type 1 Diabetes TrialNet Nutritional Intervention to Prevent (NIP) Type 1 Diabetes Study Group. Effect of Docosahexaenoic Acid (DHA) Supplementation on Inflammatory Cytokine Levels in Infants at High Genetic Risk of Type 1 Diabetes. *Pediatric Diabetes* 2015 Jun;16(4):271-9. doi: 10.1111/pedi.12170. Epub 2014 Jul 12. PMID: 25039804 PMID: PMC4291300
76. Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estominho M, Kronenberg-Versteeg D, Bingley PJ, Todd JA, Guy C, Dunger DB, Powrie J, Willcox A, Foulis AK, Richardson SJ, de Rinaldis E, Morgan NG, Lorenc A, Peakman M. Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes. *Diabetes* 2014 Nov;63(11):3835-45. doi: 10.2337/db14-0365. Epub 2014 Jun 17. PMID 24939426 PMID: PMC4207393. (TrialNet Ancillary Study)
77. Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M. Analysis of Beta Cell Death in Type 1 Diabetes by Digital Droplet PCR. *Endocrinology* 2014 Sep;155(9):3694-8. doi: 10.1210/en.2014-1150. Epub 2014 Jul 8. PMID 25004096 PMID: PMC4138562 (available 9/1/15). (TrialNet Ancillary Study)
78. Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L, and the Type 1 Diabetes TrialNet Study Group. Electrochemiluminescence Assays for Insulin and glutamic acid decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk. *Diabetes Technol Ther.* 2015 Feb;17(2):119-27. doi: 10.1089/dia.2014.0186. Epub 2015 Jan 6. PMID: 25562486 PMID: PMC4321773
79. Skyler J, Ricordi C: Perspectives in Diabetes: Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man. *Diabetes* 2011;60:1-8. PMID 21193733 PMID: PMC3012160
80. Creusot RJ, Trucco M, Clare-Salzler MJ, Fathman CG. It's Time to Bring Dendritic Cell Therapy to Type 1 Diabetes. *Diabetes* 2014;63:20-30 PMID 24357690 PMID: PMC3968436
81. Valle A, Barbagiovanni G, Jofra T, Stabilini A, Perol L, Baeyens A, Anand Santosh, Cagnard N, Nicola G, Piaggio E, Battaglia M. Heterogeneous CD3 Expression Levels in Differing T-cell Subsets Correlate with the In Vivo Anti-CD3-mediated T-cell Modulation. *J Immunol* 2015;194:2117-2127, PMID 2564630 , PMID: PMC in process. (TrialNet Ancillary Study)
82. DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye Tandy, Weinzimer SA, Bremer AA, Buckingham B for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Group. Changes in Beta Cell Function during the Proximate Post-Diagnosis Period in Persons with Type 1 Diabetes. *Pediatric Diabetes* 2015; Feb 27 Epub ahead of print. PMID 25720763 PMID: PMC as supplied by publisher.

83. Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP. The Effect of the DPT-1 Intravenous Insulin Infusion & Daily Subcutaneous Insulin on Endogenous Insulin Secretion & Post-Prandial Glucose Tolerance. *Diabetes Care* 2015 May;38(5):891-6. doi: 10.2337/dc14-1825. Epub 2015 Feb 26. PMID 25720600 PMCID: PMC 4407749
84. Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, The Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups. The Development and Utility of a Novel Scale that Quantifies the Glycemic Progression toward Type 1 Diabetes over Six Months. *Diabetes Care* 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10 PMID 25758770 PMCID: PMC4407750
85. Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. Heterogeneity in Recent Onset Type 1 Diabetes – a Clinical Trial Perspective. *Diabetes Metab Res Rev.* 2015 Feb 17. doi: 10.1002/dmrr.2643. [Epub ahead of print]. PMID 25689602 PMCID: PMC as supplied by publisher.
86. Ismail H, Krischer J, Chase HP, Cuthbertson D, Palmer J. First Test Effect in Intravenous Glucose Tolerance Testing. *Pediatric Diabetes* 2015;16:129-137. (2013, Aug 15 Epub ahead of print) PMID 23944770 PMCID: PMC3838455
87. Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM Measured Glucose Values Have a Strong Correlation with C-peptide, A1c, and IDAAC, But Do Poorly in Predicting C-peptide Levels in the Two Years Following Onset of Diabetes. *Diabetologia* 2015 Jun;58(6):1167-74. doi: 10.1007/s00125-015-3559-y. Epub 2015 Mar 14. PMID 25773405 PMCID: PMC4416994.
88. Perry D, Wasserfall C, Oram R, Williams M, Posgai A, Muir A, Haller MJ, Schatz D. Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. *Sci Rep.* 2018 Mar 14;8(1):4529. doi: 10.1038/s41598-018-22574-5. PMID: 29540798

Abstracts:

1. Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson DD, Lachin J, Skyler JS, and the DPT-1 Study Group. A Risk Score for Type 1 Diabetes Derived from Participants in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2007; 56:(Supplement 1): A-55 (Abstract 210-0)
2. Herold KC, for the Type 1 Diabetes TrialNet Study Group, the TrialNet Study Group Mechanistic Assay Committee, and the TrialNet T-Cell Assay Group. Report of the TrialNet T-Cell Validation Study in Type 1 Diabetes. *Diabetes* 2007; 56:(Supplement 1): A-319 (Abstract 1299-P)

3. Mari A, Ferrannini E, Skyler JS, and the DPT-1 Study Group. Mechanisms of Progression to Diabetes in Relatives of Type 1 Diabetic Patients. *Diabetes* 2007; 56:(Supplement 1): A-384 (Abstract 1499-P)
4. Sosenko JM, Wherrett D, Rafkin-Mervis L, Palmer JP, Skyler JS, and the DPT-1 Study Group. Metabolic Characteristics of Converters to ICA Positivity in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2007; 56:(Supplement 1): A-482 (Abstract 1907-P)
5. Mahon J, Sosenko J, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth G, Palmer J, Thompson C, Skyler J, for the Type 1 Diabetes TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study. *Diabetes* 2007; 56:(Supplement 1): A-486 (Abstract 1922-P)
6. Chase HP, Asare S, Greenbaum C, Lachin J, Lescheck E, Krause-Steinrauf H, Rafkin-Mervis L, Clare-Salzler M, for the Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes. *Diabetes* 2007; 56:(Supplement 1): A-689 (Abstract 2723-PO)
7. Krischer JP for the Type 1 Diabetes TrialNet Oral Insulin Study Group. Oral Insulin For the Prevention Of Diabetes In Relatives At Risk For Type 1 Diabetes Mellitus (T1DM). *Diabetes* 2007; 56:(Supplement 1): A-699 (Abstract 2764-PO)
8. Mahon J, Sosenko JM, Lachin J, Krause-Steinrauf H, Rafkin-Mervis L, Eisenbarth GS, Palmer JP, Thompson C, and The Type 1 Diabetes TrialNet Study Group. The Prevalence of Glucose Tolerance Abnormalities According to Autoantibody Number in the Type 1 Diabetes TrialNet Natural History Study. *Acta Diabetologia* 2007; 44:(Supplement 1): S 30.
9. Herold K for the Mechanistic Outcomes Committee and the Type 1 Diabetes TrialNet Study Group. Report from TrialNet: Diagnostic Accuracy and Reproducibility of T-Cell Responses to Islet Antigens in Subjects with Recently Diagnosed Type 1 Diabetes. *Acta Diabetologia* 2007; 44:(Supplement 1): S 21.
10. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Skyler JS, and the DPT-1 and Type 1 Diabetes TrialNet Study Groups. Comparison Between Participants of the TrialNet Natural History Study and Participants of the Diabetes prevention Trial-Type 1. *Acta Diabetologia* 2007; 44:(Supplement 1): S 50.
11. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Glucose and C-Peptide Changes in the Peri-onset Period of Type 1 Diabetes in the Diabetes Prevention Trial – Type 1 (DPT-1). *Acta Diabetologia* 2007; 44:(Supplement 1): S 49-50.

12. Ferrannini E, Nofrate V, Skyler JS, Mari A, for the DPT-1 Study Group. Progression to diabetes in relatives of people with type 1 diabetes: predictors and mode of onset. *Diabetes* 2008; 57:(Supplement 1): A-45 (Abstract 150-OR).
13. Sosenko JM, Rafkin-Mervis L, Mahon J, Lachin J, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups. Comparisons of OGTT Indices between Participants of the TrialNet Natural History Study and Participants of the Diabetes Prevention Trial-Type 1. *Diabetes* 2008; 57:(Supplement 1): A-264 (Abstract 914-P).
14. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Skyler JS, and the DPT-1 Study Group. The Loss of Post-Challenge C-Peptide Levels in the Peri-Onset Period of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2008; 57:(Supplement 1): A-502 (Abstract 1810).
15. Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer J, Cuthbertson D, Matheson D, Skyler JS, and the DPT-1 Study Group. Incident Post-Challenge Dysglycemia as a Predictor of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2008; 57:(Supplement 1): A-66 (Abstract 228-OR).
16. Triolo TM, Chase HP, Barker JM, and the DPT-1 Study Group. Subjects Diagnosed with Diabetes through the Diabetes Prevention Trial Type 1 (DPT-1) are Often Asymptomatic and Have Rare Ketosis at Onset. *Diabetes* 2008; 57:(Supplement 1): A-501-502 (Abstract 1807).
17. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group. The Timing of the Peak C-Peptide and Its Prediction of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2009; 58: (Supplement 1): Abstract 22-OR.
18. Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, Mcgee P, Krause-Steinrauf H, for the Type 1 Diabetes Trial Network (TrialNet). In Vivo Immune Responses in Type 1 Diabetes Following Treatment with Rituximab. *Diabetes* 2009; 58: (Supplement 1): Abstract 195-OR.
19. Jeffrey J, Eisenbarth GS, Fain PR, Yu L, Miao D. Persistent but Not Transient Biochemical Islet Autoantibody Expression Is Increased in Prospectively Followed Monozygotic Versus Dizygotic Twins. *Diabetes* 2009; 58: (Supplement 1): Abstract 1141-P.
20. Sosenko J, Palmer J, Rafkin-Mervis L, Krischer J, Cuthbertson D, Greenbaum C, Skyler JS, The DPT-1 Study Group. Trends of Earlier and Later C-Peptide Responses to Oral Glucose with Progression to Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). *Diabetes* 2009; 58: (Supplement 1): Abstract 1801-P.
21. Mink R, Schwartz A, Carraccio C, High P, Damman C, McGann KA, Kesselheim J, Herman B, and the Steering Committee of the Subspecialty Pediatrics Investigator Network.

Pediatric Diabetes Consortium (PDC)

Published Manuscripts:

1. Pediatric Diabetes Consortium. Pediatric Diabetes Consortium: Improving care of children with type 1 diabetes through collaborative research. *Diabetes Technol Ther* 2010 Sep;12(9):685-8. PMID: 20687862 PMID: PMC3038122
2. Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun JP, Cengiz E, Haller MJ, Hassan K, Klingensmith GJ, Tamborlane WV. The Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device. *J Diabetes Sci Technol* 2012 Mar; 6(2): 380-6. PMID: 22538150 PMID: PMC330782
3. Klingensmith GJ, Tamborlane WV, Wood J, Haller MJ, Silverstein J, Cengiz E, Shanmugham S, Kollman C, Wong-Jacobson S, Beck RW; Pediatric Diabetes Consortium. Diabetic Ketoacidosis at diabetes onset: Still an all too common threat in youth. *J Pediatr* 2013 Feb; 162(2):330-334.e1. PMID: 22901739
4. Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood JR; Pediatric Diabetes Consortium. Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. *Diabetes Technol Ther*. 2013 Nov;15(11):929-34. doi: 10.1089/dia.2013.0132. Epub 2013 Jul 19. PMID: 23869706 PMID: PMC3817890
5. Redondo MJ, Connor CG, Ruedy KJ, Beck RW, Kollman C, Wood JR, Buckingham B, Klingensmith GJ, Silverstein J, Tamborlane WV; Pediatric Diabetes Consortium. Pediatric Diabetes Consortium Type 1 Diabetes New Onset (NeOn) Study: factors associated with HbA1c levels one year after diagnosis. *Pediatr Diabetes*. 2014 Jun;15(4):294-302. doi: 10.1111/pedi.12061. Epub 2013 Jul 24. PMID: 23889707 PMID: PMC3858510
6. Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, Tamborlane WV, Lee JM, Haller MJ; Pediatric Diabetes Consortium. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. *Pediatr Diabetes*. 2014 Jun;15(4):287-93. doi: 10.1111/pedi.12068. Epub 2013 Aug 15. PMID: 23944865 PMID: PMC3844085
7. Gregg B, Connor CG, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Harris B, Tamborlane WV, Klingensmith GJ, Lee JM; Pediatric Diabetes Consortium. Body mass index changes in youth in the first year after type 1 diabetes diagnosis. *J Pediatr*. 2015

May;166(5):1265-1269.e1. doi: 10.1016/j.jpeds.2015.02.036.10.1016/j.jpeds
2015.02.036. PMID: 25919735

8. Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM; Pediatric Diabetes Consortium. C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. *Pediatr Diabetes*. 2015 May 5. doi: 10.1111/pedi.12280. [Epub ahead of print] PMID: 25940861

Abstracts:

1. Klingensmith G, Kaminski B, Block J, Cengiz E, Haller M, Lee J, Redondo M, Wood J, Tamborlane W, Beck R. Obesity and DKA are common in youth at T1D onset: findings of the Pediatric Diabetes Consortium (PDC). *Diabetes* July 2011; 60 (suppl 1): A340 (1235-P) (Poster)
2. Wood J, Kaminski B, Kollman C, Cengiz E, Haller M, Hassan K, Klingensmith G, Tamborlane W, Yun J, Beck R. The Accuracy and Precision of the Axis-Shield Afinion HbA1c Measurement Device. *Diabetes* July 2011; 60 (suppl 1): A237 (874-P) (Poster)
3. Cengiz E, Kaminski B, Klingensmith G, Haymond M, Lee J, Tamborlane W. New Insights to an Old Disease: Major Clinical Outcomes within First Year of Diagnosis for Youth with Type 1 Diabetes (T1D) from Pediatric Diabetes Consortium (PDC) Cohort. *Diabetes* July 2011; 60 (suppl 1): A334 (1216-P) (Poster)
4. Cengiz E, Kaminski B, Kollman C, Haymond M, Klingensmith G, Lee J, Tamborlane W. Frequency of Episodes of Diabetic Ketoacidosis (DKA) and Severe Hypoglycemia (SH) during the First Year after Diagnosis of Type 1 Diabetes (T1D). *Pediatr Diabetes* 2011; 12 (suppl s15):140-143(P/048/WED) (Poster)
5. Redondo R, Kaminski B, Block J, Buckingham B, Cengiz E, Haller M, Haymond M, Lee J, Schatz D, Silverstein J, Tamborlane W, Wood J, Klingensmith G. BMI in Children with Autoimmune Type 1 Diabetes. *Pediatr Diabetes* 2011; 12 (suppl s15):14-39 (O/6/FRI/02) (Oral Presentation)
6. Lin M, Wood J, Kaminski B, Pediatric Diabetes Consortium. Race and socioeconomic status are independent predictors of youth receiving insulin pump therapy in the first year of type 1 diabetes (T1D) treatment. *Pediatr Diabetes* 2011; 12 (suppl s15):14-39 (O/5/FRI/07)(Oral Presentation)
7. Cengiz E, Buckingham B, Klingensmith G, Redondo MJ, Schatz D, Tamborlane W, Wong-Jacobson S, Kollman C, Pediatric Diabetes Consortium (PDC). Partial Remission (PR) during the First 12 Months of Treatment in Youth with Type 1 Diabetes (T1D) in the Pediatric Diabetes Consortium Cohort (PDC). *Diabetes* June 2012; 61 (suppl 1): A328 (1270-P) (Poster)

8. Lin M, Wood JR, Wong-Jacobson S, Pediatric Diabetes Consortium. Race and socioeconomic status independently predict whether youth receive insulin pump therapy in the first year of type 1 diabetes (T1D) treatment. *Diabetes* June 2012; 61 (suppl 1): A324 (1253-P) (Poster)
9. Cengiz E, Wong-Jacobson S, Kollman C, Haymond M, Klingensmith G, Lee J, Tamborlane W, Pediatric Diabetes Consortium (PDC). How Common are Episodes of Diabetic Ketoacidosis (DKA) and Severe Hypoglycemia (SH) in the First Year of Diagnosis with Type 1 Diabetes (T1D) *Diabetes* June 2012; 61 (suppl 1): A328-329 (1271-P) (Poster)
10. Gregg B, Kollman C, Wong-Jacobson S, Schatz D, Cengiz E, Harris B, Tamborlane W, Klingensmith G, Lee JM, Pediatric Diabetes Consortium (PDC). Weight gain in the first year after diagnosis of type 1 diabetes. *Diabetes* June 2012; 61 (suppl 1): A325 (1258-P) (Poster)
11. Redondo MJ, Wong-Jacobson S, Buckingham B, Craig Kollman C, Klingensmith G, Silverstein JH, Tamborlane W, Wood J, Pediatric Diabetes Consortium (PDC). Characteristics of Pediatric Type 1 Diabetes (T1D) that Predict HbA1c at One Year. *Diabetes* June 2012; 61 (suppl 1): A329-330(1275-P) (Poster)
13. Wood J, Lin M, Connor C, Ruedy K, Beck R, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee J, Tamborlane W, Pediatric Diabetes Consortium. Race and socioeconomic status are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. *ATTD* 2013 (Oral Presentation)
13. Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood JR, For The Pediatric Diabetes Consortium. Race, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes. *Diabetes Technol Ther.* 2013 Jul 19. (Epub ahead of print). PMID: 23869706

T1D Exchange

Published Manuscripts

1. Pediatric Diabetes Consortium. Pediatric Diabetes Consortium: Improving care of children with type 1 diabetes through collaborative research. *Diabetes Technol Ther* 2010 Sep;12(9):685-8. PMID: 20687862 PMID: PMC3038122
2. Kaminski B, Klingensmith G, Beck R, Tamborlane W, Lee J, Hassan K, Schatz D, Kollman C, Redondo MJ, Pediatric Diabetes Consortium. Body Mass Index at the Time of Diagnosis of Autoimmune Type 1 Diabetes in Children. *J Pediatr.* 2013 Apr;162(4):736-740.e1. doi: 10.1016/j.jpeds.2012.09.017. Epub 2012 Oct 23 PMID: 23092524

3. Redondo MJ, Connor C, Ruedy KJ, Beck RW, Kollman C, Wood JR, Buckingham B, Klingensmith G, Silverstein J, Tamborlane WV, Pediatric Diabetes Consortium. Characteristics of Pediatric Type 1 Diabetes (T1D) Associated with HbA1c One Year after Diagnosis. *Pediatric Diabetes*. 2014 Jun;15(4):294-302. doi: 10.1111/pedi.12061. Epub 2013 Jul 24. PMID: 23889707 PMCID: PMC3858510
4. Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW, Cengiz E, Laffel LM, Miller KM, Haller MJ; T1D Exchange Clinic Network. A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. *Pediatr Diabetes*. 2014 Mar;15(2): 110-7. Doi: 10.1111/pedi.12067. Epub 2013 Aug 19 PMID: 23957219 PMCID: PMC4164957
5. Wood JR, Iller KM, Maahs DM, Beck RW, DiMeglio LA, Libman IM, Qinn M, Tamborlane WV, Woerner SE; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange clinic registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. *Diabetes Care*. 2013 Jul;36(7):2035-7. doi: 10.2337/dc12-1959. Epub 2013 Jan 22. PMID:23340893 PMCID:PMC3687259
6. Wong JC, Foster NC, Maahs DM, Raghinaru D, Bergenstal RM, Ahmann AJ, Peters AL, Bode BW, Aleppo G, Hirsch IB, Kleis L, Chase HP, DuBose SN, Miller KM¹, Beck RW, Adi S; T1D Exchange Clinic Network. Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry. *Diabetes Care*. 2014 Oct;37(10):2702-9. doi: 10.2337/dc14-0303. Epub 2014 Jul 10. PMID:25011947 PMCID:PMC4392936
7. Willi SM, Miller KM, DiMeglio LA, Klingensmith GJ, Simmons JH, Tamborlane WV, Nadeau KJ, Kittelsrud JM, Huckfeldt P, Beck RW, Lipman TH; T1D Exchange Clinic Network. Racial-ethnic disparities in management and outcomes among children with type 1 diabetes. *Pediatrics* 2015 Mar;135(3):424-34. doi: 10.1542/peds.2014-1774. PMID: 25687140
8. Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL, Bergenstal RM, Harris B, Dubose SN, Miller KM, Beck RW; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. *J Clin Endocrinol Metab*. 2013 Aug;98(8):3411-9. doi: 10.1210/jc.2013-1589. Epub 2013 Jun 12. PMID:23760624
9. Trief PM, Xing D, Foster NC, Maahs DM, Kittelsrud JM, Olson BA, Young LA, Peters AL, Bergenstal RM, Miller KM, Beck RW, Weinstock RS; T1D Exchange Clinic Network. Depression in adults in the T1D Exchange Clinic Registry. *Diabetes Care*. 2014 Jun;37(6):1563-72. doi: 10.2337/dc13-1867. PMID:24855157
10. Simmons JH, Chen V, Miller KM, McGill JB, Bergenstal RM, Goland RS, Harlan DM, Largay JF, Massaro EM, Beck RW; T1D Exchange Clinic Network. Differences in the management of type 1 diabetes among adults under excellent control compared with those

under poor control in the T1D Exchange Clinic Registry. *Diabetes Care*. 2013 Nov;36(11):3573-7. doi: 10.2337/dc12-2643. Epub 2013 Sep 11. PMID:24026543
PMCID:PMC3816911

11. Maahs DM, Hermann JM, DuBose SN, Miller KM, Heidtmann B, DiMeglio LA, Rami-Merhar B, Beck RW, Schober E, Tamborlane WV, Kapellen TM, Holl RW; DPV Initiative; T1D Exchange Clinic Network. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D Exchange and German/Austrian DPV registries. *Diabetologia*. 2014 Aug;57(8):1578-85. doi: 10.1007/s00125-014-3272-2. Epub 2014 Jun 4. PMID: 24893863
12. Daniels M, DuBose SN, Maahs DM, Beck RW, Fox LA, Gubitosi-Klug R, Laffel LM, Miller KM, Speer H, Tamborlane WV, Tansey MJ; T1D Exchange Clinic Network. Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry. *Diabetes Care*. 2013 Sep;36(9):2639-45. doi: 10.2337/dc12-2192. Epub 2013 Apr 22. PMID:23610082 PMCID:PMC3747908
13. Cengiz E, Xing D, Wong JC, Wolfsdorf JI, Haymond MW, Rewers A, Shanmugham S, Tamborlane WV, Willi SM, Seiple DL, Miller KM, DuBose SN, Beck RW; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. *Pediatr Diabetes*. 2013 Sep;14(6):447-54. doi: 10.1111/pedi.12030. Epub 2013 Mar 8. PMID: 23469984 PMCID: PMC4100244
14. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. *J Clin Endocrinol Metab*. 2012 Dec;97(12):4383-9. doi: 10.1210/jc.2012-1561. Epub 2012 Sep 20. PMID: 22996145

Abstracts

1. Cengiz E, Kaminski B, Klingensmith G, Haymond M, Lee J, Tamborlane W. New Insights to an Old Disease: Major Clinical Outcomes within First Year of Diagnosis for Youth with Type 1 Diabetes (T1D) from Pediatric Diabetes Consortium (PDC) Cohort. *Diabetes*. July 2011; 60 (suppl 1): A334 (1216-P). (Poster)
2. Cengiz E, Kaminski B, Kollman C, Haymond M, Klingensmith G, Lee J, Tamborlane W. Frequency of Episodes of Diabetic Ketoacidosis (DKA) and Severe Hypoglycemia (SH) during the First Year after Diagnosis of Type 1 Diabetes (T1D). *Pediatr Diabetes*. 2011; 12 (suppl s15):140-143(P/048/WED) Poster)
3. Lin M, Wood J, Kaminski B, Pediatric Diabetes Consortium. **Race** and socioeconomic

status are independent predictors of youth receiving insulin pump therapy in the first year of type 1 diabetes (T1D) treatment. *Pediatr Diabetes*. 2011; 12 (suppl s15):14-39 (O/5/FRI/07). (Oral Presentation)

4. Gregg B, Kollman C, Wong-Jacobson S, Schatz D, Cengiz E, Harris B, Tamborlane W, Klingensmith G, Lee JM, Pediatric Diabetes Consortium (PDC). Weight gain in the first year after diagnosis of type 1 diabetes. *Diabetes*. June 2012; 61 (suppl 1): A325 (1258-P) (Poster)
5. Cengiz E, Buckingham B, Klingensmith G, Redondo MJ, Schatz D, Tamborlane W, Wong-Jacobson S, Kollman C, Pediatric Diabetes Consortium (PDC). Partial Remission (PR) during the First 12 Months of Treatment in Youth with Type 1 Diabetes (T1D) in the Pediatric Diabetes Consortium Cohort (PDC). *Diabetes*. June 2012; 61 (suppl 1): A328 (1270-P) (Published). (Poster)
6. Cengiz E, Wong-Jacobson W, Kollman C, Haymond M, Klingensmith G, Lee J, Tamborlane W, Pediatric Diabetes Consortium (PDC). How Common are Episodes of Diabetic Ketoacidosis (DKA) and Severe Hypoglycemia (SH) in the First Year of Diagnosis with Type 1 Diabetes (T1D)? *Diabetes*. June 2012; 61 (suppl 1): A328-329 (1271-P) (Published). (Poster)
7. Lin MH, Wood JR, Wong-Jacobson S, Pediatric Diabetes Consortium. Race and socioeconomic status independently predict whether youth receive insulin pump therapy in the first year of type 1 diabetes (T1D) treatment. *Diabetes*. June 2012; 61 (suppl 1): A324 (1253-P). (Poster)
8. Redondo MJ, Wong-Jacobson S, Buckingham B, Kollman C, Klingensmith G, Silverstein JH, Tamborlane W, Wood J, Pediatric Diabetes Consortium (PDC). Characteristics of Pediatric Type 1 Diabetes (T1D) that Predict HbA1c at One Year. *Diabetes*. June 2012; 61 (suppl 1): A329-330(1275-P).(Poster)
10. Cengiz E, Connor C, Ruedy K, Tamborlane W, Kollman C, Beck R, Lee JM, Klingensmith G, Redondo MJ, Silverstein J, Pediatric Diabetes Consortium. Clinical Outcomes in Youth within the 2nd Year of Type 1 Diabetes: Results of the Pediatric Diabetes Consortium (PDC) T1D New Onset (NeOn) Study. ADA 2013. (Poster)
11. Wood J, Lin M, Connor C, Ruedy K, Beck R, Kollman C, Buckingham B, Redondo MJ, Schatz S, Haro H, Lee J, Tamborlane W, Pediatric Diabetes Consortium. Race and socioeconomic status are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes. *Diabetes Technol Ther* 2013 Feb;15(suppl 1):A25(O-70) (Oral Presentation)

Subspecialty Pediatrics Investigator Network

Abstracts

1. Mink RB, Carraccio CL, Herman BE, Weiss P, Turner DA, Stafford DE, Hsu DC, High PC, Fussell JJ, Curran ML, Chess PR, Schwartz A for SPIN. The link between milestone levels and fellow entrustment for the common pediatric subspecialty entrustable professional activities. Oral and poster presentation at the annual education meeting of the Accreditation Council for Graduate Medical Education, February, 2016, National Harbor, Maryland
2. Mink RB, Schwartz A, Herman BE, Turner DA, Myers AL, Kesselheim JC, Hsu DC, Curran ML, Carraccio CL for SPIN. Reliability and validity of a supervision scale for the common pediatric subspecialty entrustable professional activities. Poster presentation at the annual education meeting of the Accreditation Council for Graduate Medical Education, February, 2016, National Harbor, Maryland
3. Mink RB, Carraccio CL, Schwartz A, Dammann CE, High PC, McGann KA, Herman BE for SPIN. Creation of a pediatric subspecialty educational research network. Poster presentation at the annual spring meeting of the Association of Pediatric Program Directors, April, 2016, New Orleans
4. Mink RB, Schwartz A, Herman BE, Curran ML, Hsu DC, Kesselheim JC, Myers AL, Turner DA, Carraccio CL. Creation and validation of entrustment scales for the common pediatric subspecialty entrustable professional activities (EPAs). Oral presentation at the annual spring meeting of the Association of Pediatric Program Directors, April, 2016, New Orleans
5. Mink RB, Carraccio CL, Herman BE, Aye T, Baffa JM, Chess PR, Fussell JJ, Sauer CG, Stafford DE, Weiss P, Schwartz A for SPIN. Do fellowship program directors (FPD) and clinical competency committees (CCC) agree in fellow entrustment decisions? Poster presentation at the annual spring meeting of the Association of Pediatric Program Directors, April, 2016, New Orleans
6. Mink RB, Carraccio CL, Schwartz A, Dammann CE, High P, Kesselheim JC, McGann K, Herman BE. Establishing a medical education research network for the pediatric subspecialties. Poster presentation at annual spring meeting of the Pediatric Academic Societies, May, 2016, Baltimore, Maryland
7. Mink RB, Carraccio CL, Herman BE, Dammann C, Mahan J, Pitts S, Sauer CG, Schwartz A. Variability in fellow entrustment across the pediatric subspecialties for the common pediatric subspecialty entrustable professional activities (EPAs). Poster presentation at annual spring meeting of the Pediatric Academic Societies, May, 2016, Baltimore, Maryland

SPIN

Abstracts

1. Mink RB, Schwartz A, Herman BE, Turner DA, Curran ML, Myers A, Hsu DC, Kesselheim JC, Carraccio CL and the Steering Committee of the Subspecialty Pediatrics Investigator Network (SPIN). Validity of Level of Supervision Scales for Assessing Pediatric Fellows on the Common Pediatric Subspecialty Entrustable Professional Activities. *Acad Med.* 2017 Jul 11. doi: 10.1097/ACM.0000000000001820.
2. Mink R, Carraccio C, High P, Dammann C, McGann K, Kesselheim J, Herman B. Creating the Subspecialty Pediatrics Investigator Network (SPIN).